



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2784450 C 2016/09/13

(11)(21) **2 784 450**

(12) **BREVET CANADIEN**
CANADIAN PATENT

(13) **C**

(22) **Date de dépôt/Filing Date:** 2002/11/13

(41) **Mise à la disp. pub./Open to Public Insp.:** 2003/05/22

(45) **Date de délivrance/Issue Date:** 2016/09/13

(62) **Demande originale/Original Application:** 2 466 474

(30) **Priorité/Priority:** 2001/11/13 (US60/331,221)

(51) **Cl.Int./Int.Cl. C12N 15/31** (2006.01),
A61K 39/104 (2006.01), **A61K 39/40** (2006.01),
A61P 31/04 (2006.01), **A61P 37/04** (2006.01),
C07H 21/00 (2006.01), **C07K 14/21** (2006.01),
C07K 19/00 (2006.01), **G01N 33/564** (2006.01),
G01N 33/569 (2006.01)

(72) **Inventeurs/Inventors:**

CHARLAND, NATHALIE, CA;
HAMEL, JOSEE, CA;
BRODEUR, BERNARD R., CA;
MARTIN, DENIS, CA;
CHARLEBOIS, ISABELLE, CA;
BUSSIÈRE, DIANE, CA

(73) **Propriétaire/Owner:**

(54) **Titre : POLYPEPTIDES DE PSEUDOMONAS AERUGINOSA**

(54) **Title: POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA**

(SEQ ID NO: 2)

1 MRNPERSALL KVSGLLGSTV VAMGLGLSSA CAQKNPTVEY NQPAAPLQTK APFSGAGPAA
61 SVPAGAPNEA QPGQSFEQWR DAFRQQALAG GIDAQTFDRA FAGVQPDPAV VEADRSQPEF
121 TRPVWKYLEG ALDPLRVRQG QARLAQHARI LGEVDARYAV DADAVVAIWG MESNYGSHMG
181 NKNVIRSLAT LAYEGRRPEF AHAQLLAALK ILQHGDVPAS FMIGSWAGAM GQTQFIPTTH
241 NQYAVDFDGD GKRDIWGSPG DALASTANYL KASGWIAGQP WGFEVRLPAG FDYSLAELTI
301 RKPLGEWQGM GVQGVNGGPL PSGLSGEQAS LLLPAGHRGP AFLVLHNFRA ILKYNNSAY
361 ALAVGLLADS FKGGGRIVGA WPLEDVPLSR SQRIELQRQL AARGHDPGAV DGIIGANTRK
421 AIRACQQEFG WPADGYPTPA LLDRLRTP*

(57) **Abrégé/Abstract:**

The present invention relates to polypeptides of *Pseudomonas aeruginosa* which may be used to prevent, diagnose and/or treat *Pseudomonas aeruginosa* infection.

(73) **Propriétaires(suite)/Owners(continued):** ID BIOMEDICAL CORPORATION OF QUEBEC, CA

(74) **Agent:** SMART & BIGGAR

69140-205D

Abstract

The present invention relates to polypeptides of *Pseudomonas aeruginosa* which may be used to prevent, diagnose and/or treat *Pseudomonas aeruginosa* infection.

DEMANDES OU BREVETS VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

THIS IS VOLUME 1 OF 2

NOTE: For additional volumes please contact the Canadian Patent Office.

69140-205D

POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA

This application is a division of Canadian Application Serial No. 2,466,474 filed November 13, 2002 (parent application).

5

It should be understood that the expression "the present invention" or the like used in this specification may encompass not only the subject matter of this divisional application, but that of the parent application also.

FIELD OF THE INVENTION

10 The present invention is related to polypeptides, more particularly SPA-1, SPA-2 and SPA-3 polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.

15 **BACKGROUND OF THE INVENTION**

Pseudomonas aeruginosa is a prevalent opportunistic bacterial pathogen in humans and animals. P. aeruginosa is the most common Gram-negative bacterium found in nosocomial infections, especially in immunocompromised individuals. It is frequently 20 related to ventilator-associated pneumonia in intubated patients. Pseudomonas infection is common amongst patients with cystic fibrosis, burn wounds, organ transplants, and intravenous-drug addiction. Cystic fibrosis patients are often chronically infected by P. aeruginosa, which is responsible for 25 increased illness and death in this particular population. P. aeruginosa bacteremia is responsible for high death rates in burn units. Pseudomonas can lead to serious conditions such as endophthalmitis, endocarditis, meningitis, pneumonia, and septicaemia. Septicemia due to P. aeruginosa is associated with 30 the highest death rates of all Gram-negative infections.

Since P. aeruginosa is naturally resistant to many antibiotics, there is a need for the development of a vaccine that will protect individuals from P. aeruginosa infection. An infection 35 by P. aeruginosa induces an immune response against antigens found at the surface of the bacterial cells. However, many of these surface proteins are still not characterized, nor has the immune response resulting in protection from infection by different strains been determined.

To develop a vaccine that will protect individuals from P. aeruginosa infection, efforts have mainly been concentrated on lipopolysaccharides (LPS). However, even though a limited number of LPS serotypes are associated with clinical cases, the production of a multivalent LPS-based vaccine is complex and may

69140-205D

induce serotype replacement in vaccinated individuals. Anti-flagellar and anti-pili vaccines are also evaluated but the regulation of flagella/pili expression at different *P. aeruginosa* infection stages may prevent effective protection. 5 Outer membrane proteins (OMP) are also being tested. An OMP preparation from 4 different *P. aeruginosa* serotypes is currently in clinical trials but the specificity of the protection conferred by this preparation remains to be evaluated. A recombinant fusion protein, based on outer membrane proteins 10 OprF and OprI, is considered a promising vaccine candidate. However, the OprF protein was shown to be absent from some clinical strains of *P. aeruginosa* and the protection conferred by the OprI protein alone has not been evaluated yet.

15 A review of existing technology is described in Stanislavsky ES and Lam JS. (1997) FEMS Microbiol. Rev. 21(3): 243-77 and Holder IA. (2001) J. Burn Care Rehabil. 22(5): 311-20.

The sequence of the genome of *P. aeruginosa* strain PA01 was 20 determined in a collaboration among the Cystic Fibrosis Foundation, the University of Washington and Pathogenesis Corporation and is available in Nature, Stover et al. 406:959-964 (2000).

Therefore there remains an unmet need for *P. aeruginosa* polypeptides that may be used to prevent, diagnose and/or treat *P. aeruginosa* infection.

30

SUMMARY OF THE INVENTION

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen 35 from SEQ ID Nos: 2, 6, 8, 10, 12 or fragments or analogs thereof.

69140-205D

According to one aspect, the present invention relates to polypeptides comprising a sequence chosen from SEQ ID NO: 2, 6, 8, 10, 12 or fragments or analogs thereof.

In other aspects, there are provided polypeptides encoded by 5 polynucleotides of the invention, pharmaceutical compositions, vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and processes for producing polypeptides comprising culturing said host cells under 10 conditions suitable for expression.

The present invention as claimed relates to:

- a chimeric polypeptide comprising two or more antigenic polypeptide fragments wherein each of the two or more antigenic polypeptide fragments comprises at least 15 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:2, provided that the two or more antigenic polypeptide fragments are linked to form a chimeric polypeptide, wherein the chimeric polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid 15 sequence set forth in SEQ ID NO:2;
- a pharmaceutical composition comprising the chimeric polypeptide as described herein and a pharmaceutically acceptable carrier, diluent, adjuvant, or liposome;
- a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) an isolated polypeptide comprising (i) an amino acid sequence at 20 least 90% identical to the amino acid sequence set forth in SEQ ID NO:2, or (ii) an amino acid sequence at least 90% identical 25

69140-205D

to the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2, wherein the isolated polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in

5 SEQ ID NO:2;

- a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an isolated polypeptide comprising an antigenic fragment, wherein the antigenic fragment comprises at least 15 contiguous amino acids of the

10 amino acid sequence set forth in SEQ ID NO:2, and wherein the antigenic fragment is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2;

- the pharmaceutical composition as described herein for use in 15 inducing an immune response to the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2;

- use of the pharmaceutical composition as described herein for inducing an immune response to the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2;

20 - an antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2 for use in the prophylactic or therapeutic treatment of a *Pseudomonas aeruginosa* infection;

25 - use of an antibody, or antigen-binding fragment thereof, for the prophylactic or therapeutic treatment of a *Pseudomonas aeruginosa* infection, wherein the antibody specifically binds

69140-205D

to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2;

- a method for detecting *Pseudomonas aeruginosa* in a biological sample comprising: (a) incubating the biological sample with an

5 isolated polypeptide selected from (i) an isolated polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:2; (ii) an isolated polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth from amino acid

10 33 to amino acid 448 of SEQ ID NO:2; (iii) an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:2; (iv) an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth

15 from amino acid 33 to amino acid 448 of SEQ ID NO:2; (v) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2; (vi) an isolated polypeptide comprising the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2; and (vii) an isolated polypeptide

20 comprising an antigenic fragment wherein the fragment comprises at least 15 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:2, wherein the isolated polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in

25 SEQ ID NO:2; and (b) detecting specifically bound polypeptide which indicates the presence of antibody specific to *Pseudomonas aeruginosa* in the biological sample; and

- a method for detecting *Pseudomonas aeruginosa* in a biological sample comprising: (a) incubating the biological sample with an

30 isolated antibody or antigen-binding fragment thereof that

69140-205D

specifically binds to a *Pseudomonas aeruginosa* polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2; and (b) detecting specifically bound antibody, or antigen-binding fragment thereof, to the polypeptide, which indicates

5 the presence of *Pseudomonas aeruginosa* in the biological sample.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents the DNA sequence of SPA-1 gene from P. aeruginosa strain PA01; SEQ ID NO: 1. The underlined portion of

10 the sequence represents the leader peptide coding region.

Figure 2 represents the amino acid sequence of SPA-1 polypeptide from P. aeruginosa strain PA01; SEQ ID NO: 2. The underlined sequence represents the 32 amino acid residues leader peptide.

15 Figure 3 represents the DNA sequence of SPA-2 gene from P. aeruginosa strain PA01; SEQ ID NO: 3. The underlined portion of the sequence represents the leader peptide coding region.

Figure 4 represents the amino acid sequence of SPA-2 polypeptide from P. aeruginosa strain PA01; SEQ ID NO: 4. The underlined sequence represents the 19 amino acid residues leader peptide.

Figure 5 represents the DNA sequence of SPA-3 gene from P. aeruginosa strain PA01; SEQ ID NO: 5. The underlined portion of the sequence represents the leader peptide coding region.

25 Figure 6 represents the amino acid sequence of SPA-3 polypeptide from P. aeruginosa strain PA01; SEQ ID NO: 6. The underlined sequence represents the 21 amino acid residues leader peptide.

69140-205D

Figure 7 represents the DNA sequence of SHB-PA104 gene from P. aeruginosa strain PAO1; SEQ ID NO: 19. The underlined portion of this sequence represents the leader peptide-coding region.

Figure 8 represents the amino acid sequence of SHB-PA104 protein
5 from P. aeruginosa strain PAO1; SEQ ID NO: 20. The underlined sequence represents the 16 amino acid residues leader peptide. Figure 9 represents the DNA sequence of SHB-PA105 gene from P. aeruginosa strain PAO1; SEQ ID NO: 21. The underlined portion of the sequence represents the leader peptide-coding region.

Figure 10 represents the amino acid sequence of SHB-PA105 protein
10 from P. aeruginosa strain PAO1; SEQ ID NO: 22. The underlined sequence represents the 33 amino acid residues leader peptide.

Figure 11 represents the DNA sequence of SHB-PA106 gene from P. aeruginosa strain PAO1; SEQ ID NO: 23. The underlined portion of the sequence represents the leader peptide-coding region.

15 Figure 12 represents the amino acid sequence of SHB-PA106 protein from P. aeruginosa strain PAO1; SEQ ID NO: 24. The underlined sequence represents the 16 amino acid residues leader peptide.

Figure 13 represents the protein sequence alignment of SPA-1 protein (SEQ ID NO: 31) with SHB-PA104 (without leader peptides) from PAO1 strain
20 (SEQ ID NO: 32). |, identical amino acids; :, conserved amino acids.

Figure 14 represents the protein sequence alignment of SPA-1 protein (SEQ ID NO: 33) with SHB-PA105 (without leader peptides) from PAO1 strain (SEQ ID NO: 34). |, identical amino acids; :, conserved amino acids.

25 Figure 15 represents the protein sequence alignment of SPA-1 protein (SEQ ID NO: 35) with SHB-PA106 (without leader peptides) from PAO1 strain (SEQ ID NO: 36). |, identical amino acids; :, conserved amino acids.

WO 03/042240

PCT/CA02/01740

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides purified and isolated polynucleotides, which encode Pseudomonas polypeptides which may be used to prevent, diagnose and/or treat Pseudomonas infection.

5

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or 10 analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence 15 chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 20 90% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

According to one aspect, the present invention provides an 25 isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

30 According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 98% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

35

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

WO 03/042240

PCT/CA02/01740

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence 5 chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 90% identity to a second polypeptide comprising SEQ ID NOS: 2, 10 4, 6, 8, 10 or 12.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID NOS: 2, 15 4, 6, 8, 10 or 12.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 98% identity to a second polypeptide comprising SEQ ID NOS: 2, 20 4, 6, 8, 10 or 12.

According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

25

According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 10 or 12.

30 According to one aspect, the present invention relates to polypeptides characterized by the amino acid sequence comprising SEQ ID NOS: 2, 4, 6, 8, 10; 12 or fragments or analogs thereof.

According to one aspect, the present invention relates to 35 polypeptides characterized by the amino acid sequence comprising SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a

WO 03/042240

PCT/CA02/01740

polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

According to one aspect, the present invention provides a 5 polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

According to one aspect, the present invention relates to 10 epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof.

According to one aspect, the present invention relates to 15 epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

According to one aspect, the present invention provides an isolated polynucleotide comprising a polynucleotide chosen from:

- 20 (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;
- (b) a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;
- (c) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;
- (d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;
- 35 (e) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;

WO 03/042240

PCT/CA02/01740

- (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof;
- (g) a polynucleotide comprising a sequence chosen from SEQ ID NOS: 1, 3, 5, 7, 9, 11 or fragments or analogs thereof;
- (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an 10 isolated polynucleotide comprising a polynucleotide chosen from:

- (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (b) a polynucleotide encoding a polypeptide having at least 80% 15 identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (c) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (d) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (e) a polynucleotide encoding a polypeptide capable of raising 20 antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (f) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (g) a polynucleotide comprising a sequence chosen from SEQ ID 25 NOS: 1, 3, 5, 7, 9 or 11;
- (h) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

According to one aspect, the present invention provides an 35 isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;

WO 03/042240

PCT/CA02/01740

- (b) a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;
- (c) a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;
- (d) a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;
- (f) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 or fragments or analogs thereof;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.

20

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- (a) a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (b) a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (c) a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (d) a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (e) a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;
- (f) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12;

WO 03/042240

PCT/CA02/01740

- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- (h) the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.

5

Those skilled in the art will appreciate that the invention includes DNA molecules, i.e. polynucleotides, their homologous sequences and their complementary sequences that encode analogs such as mutants, variants, homologs and derivatives of such 10 polypeptides, as described herein in the present patent application. Homologous genes are evolutionary related, have similar sequences and are structurally related. The invention also includes RNA molecules corresponding to the DNA molecules of the invention. In addition to the DNA and RNA molecules, the 15 invention includes the corresponding polypeptides and monospecific antibodies that specifically bind to such polypeptides.

In a further embodiment, the polypeptides in accordance with the 20 present invention are antigenic.

In a further embodiment, the polypeptides in accordance with the present invention are immunogenic.

25 In a further embodiment, the polypeptides in accordance with the present invention can elicit an immune response in a host.

In a further embodiment, the present invention also relates to polypeptides which are able to raise antibodies having binding 30 specificity to the polypeptides of the present invention as defined above.

An antibody that "has binding specificity" is an antibody that recognizes and binds the selected polypeptide but which does not 35 substantially recognize and bind other molecules in a sample, e.g., a biological sample. Specific binding can be measured using an ELISA assay in which the selected polypeptide is used as an antigen.

WO 03/042240

PCT/CA02/01740

In accordance with the present invention, "protection" in the biological studies is defined by a significant increase in the survival curve, rate or period. Statistical analysis using the Log rank test to compare survival curves, and Fisher exact test 5 to compare survival rates and numbers of days to death, respectively, might be useful to calculate P values and determine whether the difference between the two groups is statistically significant. P values of 0.05 are regarded as not significant.

10

In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the polypeptides of the invention, or of analogs thereof.

15 The fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical 20 to a particular part of a polypeptide or analog thereof as described herein. The present invention further provides fragments having at least 10 contiguous amino acid residues from the polypeptide sequences of the present invention. In one embodiment, at least 15 contiguous amino acid residues. In one 25 embodiment, at least 20 contiguous amino acid residues.

The skilled person will appreciate that analogs of the polypeptides of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic 30 material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention.

As used herein, "fragments", "analog" or "derivatives" of the 35 polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural. In one embodiment, derivatives and analogs of polypeptides of the

WO 03/042240

PCT/CA02/01740

invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% identity. In a further 5 embodiment, polypeptides will have greater than 85% identity. In a further embodiment, polypeptides will have greater than 90% identity. In a further embodiment, polypeptides will have greater than 95% identity. In a further embodiment, polypeptides will have greater than 99% identity. In a further 10 embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

In a further embodiment, polypeptides will have greater than 70% 15 homology. In a further embodiment, polypeptides will have greater than 75% homology. In a further embodiment, polypeptides will have greater than 80% homology. In a further embodiment, polypeptides will have greater than 85% homology. In a further embodiment, polypeptides will have greater than 90% homology. In a further 20 embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, derivatives and analogs of polypeptides of the invention will have less than about 20 amino acid residue substitutions, modifications or 25 deletions and more preferably less than 10. Preferred substitutions are those known in the art as conserved i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional groups.

30 These substitutions are those having a minimal influence on the secondary structure and hydropathic nature of the polypeptide. Preferred substitutions are those known in the art as conserved, i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional 35 groups. These include substitutions such as those described by Dayhoff, M. in *Atlas of Protein Sequence and Structure 5*, 1978 and by Argos, P. in *EMBO J. 8*, 779-785, 1989. For example, amino acids, either natural or unnatural, belonging to one of the following groups represent conservative changes:

WO 03/042240

PCT/CA02/01740

ala, pro, gly, gln, asn, ser, thr, val;
cys, ser, tyr, thr;
val, ile, leu, met, ala, phe;
lys, arg, orn, his;
5 and phe, tyr, trp, his.

The preferred substitutions also include substitutions of D-enantiomers for the corresponding L-amino acids.

In an alternative approach, the analogs could be fusion polypeptides, incorporating moieties which render purification 10 easier, for example by effectively tagging the desired polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

15 The percentage of homology is defined as the sum of the percentage of identity plus the percentage of similarity or conservation of amino acid type.

In one embodiment, analogs of polypeptides of the invention will 20 have about 70% homology with those sequences illustrated in the figures or fragments thereof. In a further embodiment, polypeptides will have greater than 80% homology. In a further embodiment, polypeptides will have greater than 85% homology. In a further embodiment, polypeptides will have greater than 90% 25 homology. In a further embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, 30 modifications or deletions and more preferably less than 10.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either 35 sequence as appropriate. It is possible to calculate amino acid identity or homology for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each

WO 03/042240

PCT/CA02/01740

having a different score. Both types of identity analysis are contemplated in the present invention.

In an alternative approach, the analogs or derivatives could be 5 fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired protein or polypeptide, it may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

10

It is well known that it is possible to screen an antigenic polypeptide to identify epitopic regions, i.e. those regions which are responsible for the polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are 15 well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties.

20 In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of analogs or derivatives thereof.

Thus, what is important for analogs, derivatives and fragments 25 is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

Also included are polypeptides which have fused thereto other 30 compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for ease of purification; prepro- and pro- sequences; and (poly)saccharides.

35

Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different Pseudomonas strains.

Moreover, the polypeptides of the present invention can be modified by terminal -NH₂ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. 5 with ammonia or methylamine) to provide stability, increased hydrophobicity for linking or binding to a support or other molecule.

Also contemplated are hetero and homo polypeptide multimers of 10 the polypeptide fragments and analogs. These polymeric forms include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, gluteraldehyde or dimethylsulfoxide. Such polymeric forms also include polypeptides containing two or more tandem or 15 inverted contiguous sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.

In a further embodiment, the present invention also relates to 20 chimeric polypeptides which comprise one or more polypeptides or fragments or analogs thereof as defined in the figures of the present application.

In a further embodiment, the present invention also relates to 25 chimeric polypeptides comprising two or more polypeptides having a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.

In a further embodiment, the present invention also relates to 30 chimeric polypeptides comprising two or more polypeptides comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12 provided that the polypeptides are linked as to form a chimeric polypeptide.

35 Preferably, a fragment, analog or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e. at least one epitope.

WO 03/042240

PCT/CA02/01740

In order to achieve the formation of antigenic polymers (i.e. synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like, where the reagents being specific for thio groups. Therefore, the link 5 between two mercapto groups of the different polypeptides may be a single bond or may be composed of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

10 In a particular embodiment, polypeptide fragments and analogs of the invention do not contain a methionine (Met) starting residue. Preferably, polypeptides will not incorporate a leader or secretory sequence (signal sequence). The signal portion of a polypeptide of the invention may be determined according to 15 established molecular biological techniques. In general, the polypeptide of interest may be isolated from a Pseudomonas culture and subsequently sequenced to determine the initial residue of the mature protein and therefore the sequence of the mature polypeptide.

20

Such an immunogenic fragment may include, for example, the polypeptide of the invention lacking an N-terminal leader peptide, and/or a transmembrane domain and/or external loops and/or turns.

25

The present invention further provides a fragment of the polypeptide comprising substantially all of the extra cellular domain of a polypeptide which has at least 70% identity, preferably 80% identity, more preferably 95% identity, to a 30 second polypeptide comprising Seq. ID No. 2, 4, 6, 8, 10, 12 or fragments or analogs thereof, over the entire length of said sequence.

It is understood that polypeptides can be produced and/or used 35 without their start codon (methionine or valine) and/or without their leader peptide to favor production and purification of recombinant polypeptides. It is known that cloning genes without sequences encoding leader peptides will restrict the

WO 03/042240

PCT/CA02/01740

polypeptides to the cytoplasm of *E. coli* and will facilitate their recovery (Glick, B.R. and Pasternak, J.J. (1998) Manipulation of gene expression in prokaryotes. In "Molecular biotechnology: Principles and applications of recombinant DNA", 5 2nd edition, ASM Press, Washington DC, p.109-143).

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polypeptide of the invention, together with a carrier, diluent or adjuvant; 10 (ii) a pharmaceutical composition comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iii) a vaccine comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iv) a method for inducing an immune response against Pseudomonas, in a host, by administering to the 15 host, an immunogenically effective amount of a polypeptide of the invention to elicit an immune response, e.g., a protective immune response to Pseudomonas; and particularly, (v) a method for preventing and/or treating a Pseudomonas infection, by administering a prophylactic or therapeutic amount of a 20 polypeptide of the invention to a host in need.

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polynucleotide of the invention, together with a carrier, diluent or adjuvant; 25 (ii) a pharmaceutical composition comprising a polynucleotide of the invention and a pharmaceutically acceptable carrier, diluent or adjuvant; (iii) a method for inducing an immune response against Pseudomonas, in a host, by administering to the host, an immunogenically effective amount of a polynucleotide of the 30 invention to elicit an immune response, e.g., a protective immune response to Pseudomonas; and particularly, (iv) a method for preventing and/or treating a Pseudomonas infection, by administering a prophylactic or therapeutic amount of a polynucleotide of the invention to a host in need.

35

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polypeptide of the invention, together with a liposome, carrier, diluent or

WO 03/042240

PCT/CA02/01740

adjuvant; (ii) a pharmaceutical composition comprising a polypeptide of the invention and a liposome, carrier, diluent or adjuvant; (iii) a vaccine comprising a polypeptide of the invention and a liposome, carrier, diluent or adjuvant; (iv) a 5 *method for inducing an immune response against P. aeruginosa*, in a host, by administering to the host, an immunogenically effective amount of a pharmaceutical composition of the invention to elicit an immune response, e.g., a protective immune response to P. aeruginosa; and particularly, (v) a method 10 for preventing and/or treating a P. aeruginosa infection, by administering a prophylactic or therapeutic amount of a pharmaceutical composition of the invention to a host in need.

According to another aspect of the invention, there are also 15 provided (i) a composition of matter containing a polynucleotide of the invention, together with a liposome, carrier, diluent or adjuvant; (ii) a pharmaceutical composition comprising a polynucleotide of the invention and a liposome, carrier, diluent or adjuvant; (iii) a method for inducing an immune response 20 against P. aeruginosa, in a host, by administering to the host, an immunogenically effective amount of a pharmaceutical composition of the invention to elicit an immune response, e.g., a protective immune response to P. aeruginosa; and particularly, (iv) a method for preventing and/or treating a P. 25 aeruginosa infection, by administering a prophylactic or therapeutic amount of a pharmaceutical composition of the invention to a host in need.

In a further embodiment, the polypeptides of the invention are 30 associated with the liposomes.

As used herein, "associated with" means that the polypeptides of the invention are at least partially embedded in the liposome membrane, and preferably are not covalently linked to the 35 lipids. The polypeptides may also be bonded to a lipid fatty acid "tail" which itself is embedded in the membrane.

WO 03/042240

PCT/CA02/01740

In a further embodiment, the pharmaceutical compositions comprising a liposome associated with polypeptides in accordance with the present invention are antigenic.

5 In a further embodiment, the pharmaceutical compositions comprising a liposome associated with polypeptides in accordance with the present invention are immunogenic.

In a further embodiment, the pharmaceutical compositions 10 comprising a liposome associated with polypeptides in accordance with the present invention can elicit an immune response in a host.

In a further embodiment, the present invention also relates to 15 pharmaceutical compositions comprising a liposome associated with polypeptides which are able to raise antibodies having binding specificity to the polypeptides of the present invention as defined above.

20 In an additional aspect of the invention there are provided pharmaceutical compositions comprising a liposome associated with immunogenic and/or antigenic fragments of the polypeptides of the invention, or of analogs thereof.

25 The present invention further provides pharmaceutical compositions comprising a liposome associated with fragments which comprise a B-cell or T-helper epitope.

The present invention further provides pharmaceutical 30 compositions comprising a liposome associated with fragment that may be part of a larger polypeptide. It can be advantageous to include an additional amino acid sequence which contains secretory or leader sequences, or sequences which aid in purification such as multiple histidine residues, or an 35 additional sequence which increases stability during recombinant production, or an additional polypeptide or lipid tail sequences

WO 03/042240

PCT/CA02/01740

which increase the immunogenic potential of the final polypeptide.

The skilled person will appreciate that pharmaceutical compositions comprising a liposome associated with analogs of the polypeptides of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention.

In a further embodiment, the present invention also relates to pharmaceutical compositions comprising a liposome associated with chimeric polypeptides which comprise one or more polypeptides or fragments or analogs thereof of the invention.

Liposomes are made of phospholipids and other polar amphiles, which form closed concentric bilayer membranes [summarized in Gregoriades, G., *Immunology Today*, 11, 3, 89 (1990); Lasic, D., 20 *American Scientist*, 80, p. 20 (1992); Remington's on *Pharmaceutical Sciences*, 18th ed., 1990, Mack Publishing Co., Pennsylvania., p.1691]. The primary constituent of liposomes are lipids, which have a polar hydrophilic "head" attached to a long, nonpolar, hydrophobic "tail". The hydrophilic head 25 typically consists of a phosphate group, while the hydrophobic tail is made of two long hydrocarbon chains. Since the lipid molecules have one part that is water-soluble and another part that is not, they tend to aggregate in ordered structures that sequester the hydrophobic tails from water molecules. In the 30 process, liposomes can entrap water and solutes in their interior, or molecules with hydrophobic regions can also be incorporated directly into the liposomal membranes. Many phospholipids, alone or in combination, with other lipids will 35 form liposomes. By convention, liposomes are categorized by size, and a 3-letter acronym is used to designate the type of liposome being discussed. Multilamellar vesicles are designated "MLV", large unilamellar vesicles "LUV", small unilamellar

WO 03/042240

PCT/CA02/01740

vesicles "SUV". These designations are sometimes followed by the chemical composition of the liposome. Nomenclature and a summary of known liposomes is described in Storm et al, 1998, PSIT, 1:19-31. Liposomes are efficient in helping membrane proteins 5 refolding and are also efficient adjuvant boosting the humoral as well as the cellular immune response against an antigen.

The invention provides pharmaceutical compositions comprising liposomes constituted from phospholipids. These phospholipids 10 can be synthetized or extracted from bacterial cells, soybean, eggs.

The invention provides a process for the incorporation of polypeptides of the invention into different liposome 15 formulations.

Liposomes can be prepared with various synthetic phospholipids (List 1) or bacterial phospholipids and/or cholesterol, which can be combined at different ratios.

20

The invention provides a method for extracting lipids from bacterial cells in order to generate liposome formulations from bacterial origin. Complex lipid mixtures can be extracted from several bacterial species. These species could include but are 25 not limited to : Neisseria spp, Haemophilus spp, Pseudomonas spp, Bacterioides spp, Legionella spp, Vibrio spp, Brucella spp, Bordetella spp, Campylobacter spp, Klebsiella spp, Salmonella spp, Shigella spp, Proteus spp, and Yersinia spp. Other species can be found in Bergey's Manual of Determinative Bacteriology 30 (1974) (Baltimore).

The liposomes of the invention can be prepared from a variety of vesicle-forming lipids including phosphatidyl ethers and esters, such as phosphatidylethanolamine (PE), phosphatidylserine (PS), 35 phosphatidylglycerol (PG) and phosphatidylcholine (PC) but also from glycerides, such as dioleoylglycerosuccinate; cerebrosides; gangliosides, sphingomyelin; steroids, such as cholesterol; and

21

WO 03/042240

PCT/CA02/01740

other lipids, as well as excipients such as Vitamin E or Vitamin C palmitate.

The fluidity and stability of the liposomal membrane will depend 5 on the transition temperature (temperature at which hydrocarbon regions change from a quasicrystalline to a more fluid state) of the phospholipids.

Modifications of membrane fluidity, number of lamellae, vesicle 10 size, surface charge, lipid to antigen ratio and localization of the antigen within the liposome can modulate the adjuvanticity of liposomal preparations.

The preparation of liposomes can be made by a number of 15 different techniques including ethanol injection; ether infusion; detergent removal; solvent evaporation; evaporation of organic solvents from chloroform in water emulsions; extrusion of multilamellar vesicles through a nucleopore polycarbonate membrane; freezing and thawing of phospholipid mixtures, as well 20 as sonication and homogenization.

Lipids can be dissolved in a suitable organic solvent or mixture 25 of organic solvents, such as a chloroform:methanol solution in a round bottom glass flask and dried using a rotatory evaporator to achieve an even film on the vessel.

Before immunization, the polypeptides of the invention can also be coupled or conjugated to carrier proteins such as tetanus toxin, diphtheria toxin, hepatitis B virus surface antigen, 30 poliomyelitis virus VP1 antigen or any other viral or bacterial toxin or antigen or any suitable proteins to stimulate the development of a stronger immune response. This coupling or conjugation can be done chemically or genetically. A more detailed description of peptide-carrier conjugation is available 35 in Van Regenmortel, M.H.V., Briand J.P., Muller S., Plaué S., «Synthetic Polypeptides as antigens» in Laboratory Techniques in

WO 03/042240

PCT/CA02/01740

Biochemistry and Molecular Biology, Vol.19 (ed.) Burdou, R.H. & Van Knippenberg P.H. (1988), Elsevier New York.

According to another aspect, there are provided pharmaceutical compositions comprising one or more Pseudomonas polypeptides of the invention in a mixture with a pharmaceutically acceptable adjuvant. Suitable adjuvants include (1) oil-in-water emulsion formulations such as MF59™, SAF™, Ribi™ ; (2) Freund's complete or incomplete adjuvant; (3) salts i.e. AlK(SO₄)₂, AlNa(SO₄)₂, 10 AlNH₄(SO₄)₂, Al(OH)₃, AlPO₄, silica, kaolin; (4) saponin derivatives such as Stimulon™ or particles generated therefrom such as ISCOMs (immunostimulating complexes); (5) cytokines such as interleukins, interferons, macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF) ; (6) other 15 substances such as carbon polynucleotides i.e. poly IC and poly AU, detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal immunity; (7) liposomes. A more detailed description of adjuvants is available in a review by M.Z.I Khan et al. in Pharmaceutical Research, vol. 11, No. 1 20 (1994) pp2-11, and also in another review by Gupta et al., in Vaccine, Vol. 13, No. 14, pp1263-1276 (1995) and in WO 99/24578. Preferred adjuvants include QuilA™, QS21™, Alhydrogel™ and Adjuphos™.

25 Pharmaceutical compositions of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or buccal or oral.

The term "pharmaceutical composition" is also meant to include 30 antibodies. In accordance with the present invention, there is also provided the use of one or more antibodies having binding specificity for the polypeptides of the present invention for the treatment or prophylaxis of Pseudomonas infection and/or diseases and symptoms mediated by Pseudomonas infection.

35

Pharmaceutical compositions of the invention are used for the prophylaxis of Pseudomonas infection and/or diseases and symptoms mediated by Pseudomonas infection as described in Manual of Clinical Microbiology, P.R. Murray (Ed, in chief), E.J.

WO 03/042240

PCT/CA02/01740

Baron, M.A. Pfaller, F.C. Tenover and R.H. Yolken. ASM Press, Washington, D.C. seventh edition, 1999, 1773p. and in Campa, M. et al. (Eds.) Pseudomonas aeruginosa as an opportunistic pathogen (1993) Plenum Press, NY, 419 p.

5

In one embodiment, pharmaceutical compositions of the present invention are used for the treatment or nosocomial infections, especially in immunocompromised individuals such as ventilator-associated pneumonia in intubated patients, bacteremia in burned 10 patients, chronic infection in cystic fibrosis patients and septicemia. In one embodiment, pharmaceutical compositions of the invention are used for the treatment or prophylaxis of Pseudomonas infection and/or diseases and symptoms mediated by Pseudomonas infection. In a further embodiment, the Pseudomonas 15 infection is mediated by Pseudomonas aeruginosa. In a further embodiment, the Pseudomonas infection is mediated by Pseudomonas stutzeri.

In a particular embodiment, pharmaceutical compositions are 20 administered to those hosts at risk of Pseudomonas infection such as infants, elderly and immunocompromised hosts and also hospitalized patients, cystic fibrosis patients, people susceptible to be burnt such as firemen, military personnel.

25 As used in the present application, the term "host" includes mammals. In a further embodiment, the mammal is human.

Pharmaceutical compositions are preferably in unit dosage form of about 0.001 to 100 μ g/kg (antigen/body weight) and more 30 preferably 0.01 to 10 μ g/kg and most preferably 0.1 to 1 μ g/kg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

Pharmaceutical compositions are preferably in unit dosage form 35 of about 0.1 μ g to 10 mg and more preferably 1 μ g to 1 mg and most preferably 10 to 100 μ g 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

WO 03/042240

PCT/CA02/01740

According to another aspect, there are provided polynucleotides encoding polypeptides characterized by the amino acid sequence comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

5

In one embodiment, polynucleotides are those illustrated in SEQ ID Nos: 1, 3, 5, 7, 9, 11 which may include the open reading frames (ORF), encoding the polypeptides of the invention.

10 It will be appreciated that the polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention. Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described 15 (or the complement sequences thereof) having 70% identity between sequences. In one embodiment, at least 80% identity between sequences. In one embodiment, at least 85% identity between sequences. In one embodiment, at least 90% identity between sequences. In a further embodiment, polynucleotides are 20 hybridizable under stringent conditions i.e. having at least 95% identity. In a further embodiment, more than 97% identity.

Suitable stringent conditions for hybridization can be readily determined by one of skilled in the art (see for example Sambrook et al., (1989) Molecular cloning : A Laboratory Manual, 25 2nd ed, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology, (1999) Edited by Ausubel F.M. et al., John Wiley & Sons, Inc., N.Y.).

In a further embodiment, the present invention provides 30 polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a polypeptide;

35 wherein said polypeptide comprises a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

WO 03/042240

PCT/CA02/01740

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

5 (a) a DNA sequence encoding a polypeptide or
 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs 10 thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

15 (a) a DNA sequence encoding a polypeptide or
 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen 20 from SEQ ID NOS: 2, 4, 6, 8, 10, 12 or fragments or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to 25 either

(a) a DNA sequence encoding a polypeptide or
 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino 30 acid residues from a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10 or 12.

In a further embodiment, polynucleotides are those encoding polypeptides of the invention illustrated in SEQ ID NOS: 2, 4, 35 6, 8, 10, 12.

In a further embodiment, polynucleotides are those illustrated in SEQ ID NOS: 1, 3, 5, 7, 9, 11 encoding polypeptides of the invention.

WO 03/042240

PCT/CA02/01740

As will be readily appreciated by one skilled in the art, polynucleotides include both DNA and RNA.

5 The present invention also includes polynucleotides complementary to the polynucleotides described in the present application.

According to another aspect, there is provided a process for 10 producing polypeptides of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product. Alternatively, the polypeptides can be produced according to established synthetic chemical techniques 15 i.e. solution phase or solid phase synthesis of oligopeptides which are ligated to produce the full polypeptide (block ligation).

General methods for obtention and evaluation of polynucleotides 20 and polypeptides are described in the following references: Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York; PCR Cloning Protocols, from Molecular Cloning to 25 Genetic Engineering, Edited by White B.A., Humana Press, Totowa, New Jersey, 1997, 490 pages; Protein Purification, Principles and Practices, Scopes R.K., Springer-Verlag, New York, 3rd Edition, 1993, 380 pages; Current Protocols in Immunology, Edited by Coligan J.E. et al., John Wiley & Sons Inc., New York.

30

The present invention provides host cells transfected with vectors comprising the polynucleotides of the invention.

The present invention provides a process for producing a 35 polypeptide comprising culturing a host cell of the invention under conditions suitable for expression of said polypeptide.

For recombinant production, host cells are transfected with vectors which encode the polypeptides of the invention, and then

WO 03/042240

PCT/CA02/01740

cultured in a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable in the chosen host and include chromosomal, non-chromosomal and 5 synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the appropriate site using restriction enzymes such that it is operably linked to an 10 expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and optionally an operator (control element). One can select individual components of the expression control region that are appropriate for a given host and vector according to established 15 molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York). Suitable promoters include but are not limited to LTR or SV40 promoter, *E.coli* lac, 20 tac or trp promoters and the phage lambda P_i promoter. Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicillin resistance gene. Suitable bacterial vectors include pET, pQE70, pQE60, pQE-9, pD10 phagescript, psIX174, pbluescript SK, pbsks, pNH8A, pNH16a, 25 pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. *E.coli*, *Bacillus subtilis*, *Streptomyces*; fungal i.e. *Aspergillus niger*, *Aspergillus nidulans*; yeast i.e. 30 *Saccharomyces* or eukaryotic i.e. CHO, COS.

Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by physical or chemical means (if the expressed polypeptide is not secreted 35 into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the properties of the polypeptide i.e. using ammonium sulfate or ethanol

WO 03/042240

PCT/CA02/01740

precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final purification may be achieved using 5 HPLC.

The polypeptides may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US 4,431,739; 10 US 4,425,437; and US 4,338,397) or be chemically removed subsequent to purifying the expressed polypeptide.

According to a further aspect, the Pseudomonas polypeptides of the invention may be used in a diagnostic test for Pseudomonas 15 infection, in particular Pseudomonas aeruginosa infection.

Several diagnostic methods for Pseudomonas infection in an host susceptible to Pseudomonas infection are possible, for example detecting Pseudomonas organism in a biological sample, the 20 following procedure may be followed:

- a) obtaining a biological sample from a host;
- b) incubating an antibody or fragment thereof reactive with a Pseudomonas polypeptide of the invention with the biological sample to form a mixture; and
- 25 c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of Pseudomonas.

Alternatively, a method for diagnostic for Pseudomonas infection in an host susceptible to Pseudomonas infection includes a 30 method for the detection of antibody specific to a Pseudomonas antigen in a biological sample containing or suspected of containing said antibody may be performed as follows:

- a) obtaining a biological sample from a host;
- b) incubating one or more Pseudomonas polypeptides of the 35 invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to Pseudomonas.

One of skill in the art will recognize that this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay 5 or a latex agglutination assay, essentially to determine whether antibodies specific for the polypeptide are present in an organism.

The DNA sequences encoding polypeptides of the invention may 10 also be used to design DNA probes for use in detecting the presence of Pseudomonas in a biological sample suspected of containing such bacteria. The detection method of this invention comprises:

- a) obtaining the biological sample from a host;
- 15 b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound DNA probe in the mixture which indicates the presence of Pseudomonas bacteria.

20

The DNA probes of this invention may also be used for detecting circulating Pseudomonas i.e. Pseudomonas nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing Pseudomonas infections. The probe may be 25 synthesized using conventional techniques and may be immobilized on a solid phase, or may be labelled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the Pseudomonas polypeptides of the invention. In 30 a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 15 contiguous nucleotides of the Pseudomonas polypeptides of the invention. In a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 35 30 contiguous nucleotides of the Pseudomonas polypeptides of the invention. In a further embodiment, the preferred DNA probe will be an oligomer having a sequence complementary to at least about 50 contiguous nucleotides of the Pseudomonas polypeptides of the invention.

Another diagnostic method for the detection of Pseudomonas in a host comprises:

- a) labelling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;
- 5 b) administering the labelled antibody or labelled fragment to the host; and
- c) detecting specifically bound labelled antibody or labelled fragment in the host which indicates the presence of

10 Pseudomonas.

In a further aspect, polynucleotides encoding polypeptides of the invention, or fragments, analogs or derivatives thereof, may be used in a DNA immunization method. That is, they can be 15 incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is 20 injected intramuscularly.

A further aspect of the invention is the use of the Pseudomonas polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of Pseudomonas infection.

25

A further aspect of the invention is the use of the antibodies directed to the polypeptides of the invention for passive immunization, whereby an antibody raised by a polypeptide of the invention is administered to a host in an amount sufficient to 30 provide a passive immunization. One could use the antibodies described in the present application. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against Pseudomonas infection in a test model. One 35 example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class. The antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically

WO 03/042240

PCT/CA02/01740

of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term recombinant antibody or antibody fragment means antibody or antibody fragment which was produced 5 using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the Pseudomonas polypeptides but is preferably specific for one.

10 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method or system such as direct injection of plasmid DNA into muscles [Wolf et al. H M G (1992) 1: 363; Turnes et al., Vaccine (1999), 17 : 2089; Le et al., Vaccine (2000) 18 : 1893; Alves et al., 15 Vaccine (2001) 19 : 788], injection of plasmid DNA with or without adjuvants [Ulmer et al., Vaccine (1999) 18: 18; MacLaughlin et al., J. Control Release (1998) 56: 259; Hartikka et al., Gene Ther. (2000) 7: 1171-82; Benvenisty and Reshef, PNAS USA (1986) 83:9551; Singh et al., PNAS USA (2000) 97: 811], 20 targeting cells by delivery of DNA complexed with specific carriers [Wa et al., J Biol Chem (1989) 264: 16985; Chaplin et al., Infect. Immun. (1999) 67: 6434], injection of plasmid complexed or encapsulated in various forms of liposomes [Ishii et al., AIDS Research and Human Retroviruses (1997) 13: 142; 25 Perrie et al., Vaccine (2001) 19: 3301], administration of DNA with different methods of bombardment [Tang et al., Nature (1992) 356: 152; Eisenbraun et al., DNA Cell Biol (1993) 12: 791; Chen et al., Vaccine (2001) 19: 2908], and administration of DNA with lived vectors [Tubulekas et al., Gene (1997) 190: 30 191; Pushko et al., Virology (1997) 239: 389; Spreng et al. FEMS (2000) 27: 299; Dietrich et al., Vaccine (2001) 19: 2506].

In a further aspect, the invention provides a method for prophylactic or therapeutic treatment of Pseudomonas infection 35 in a host susceptible to Pseudomonas infection comprising administering to the host a prophylactic or therapeutic amount of a pharmaceutical composition of the invention.

69140-205D

In a further embodiment, the invention provides the use of a pharmaceutical composition of the invention in the manufacture of a medicament for the prophylactic or therapeutic treatment of Pseudomonas infection.

5

In a further embodiment, the invention provides a kit comprising a polypeptide of the invention for detection or diagnosis of Pseudomonas infection.

10 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are 15 illustrative only and not intended to be limiting.

20 **EXAMPLE 1**

This example illustrates the cloning and molecular characteristics of SPA-1 gene and corresponding polypeptide.

The coding region of P. aeruginosa SPA-1 (SEQ ID NO: 1) gene was 25 amplified by PCR (Hybaid PCR Express, ESBE Scientific, Markham, Ontario, Canada) from genomic DNA of P. aeruginosa strain PA01 using the following oligos that contained base extensions for the addition of restriction sites NdeI (CATATG) and NotI (GCGGCCGC): PSEU59 (5'- GGGATTCCATATGGCGCAGAAGAATCCGACAGTCG -3') and 30 PSEU60 (5'- ATAAGAATGCGGCCGCTGGCGTCCGCAGGCGGT -3'). PCR products were purified from agarose gel using a QIAquick gel extraction kit following the manufacturer's instructions (Qiagen, Chatsworth, CA), and digested with NdeI and NotI (Amersham Pharmacia Biotech, Inc, Baie d'Urfé, Canada). The pET21b(+) vector 35 (Novagen, Madison, WI) was digested with NdeI and NotI and purified from agarose gel using a QIAquick gel extraction kit (Qiagen). The NdeI-NotI PCR products were ligated to the NdeI-NotI pET21b(+) expression vector. The ligated products were transformed into E. coli strain DH5 α [φ80dlacZΔM15 Δ(lacZYA-

WO 03/042240

PCT/CA02/01740

argF)U169 *endA1* *recA1* *hsdR17(r_k-m_k +)* *deoR* *thi-1* *supE44* λ -*gyrA96* *relA1*] (Gibco BRL, Gaithersburg, MD) according to the method of Simanis (Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). Recombinant pET21b(+) plasmid (rpET21b(+)) containing 5 SPA-1 gene was purified using a Qiagen kit and DNA insert was sequenced (Taq Dye Deoxy Terminator Cycle Sequencing kit, ABI, Foster City, CA).

10 Table 1. Oligonucleotide primers used for PCR amplification of P. aeruginosa genes.

Genes	Primers I.D.	Restriction site	Vector	Sequence	Sequence I.D. No.
SPA-1	PSEU59	<i>Nde</i> I	pET21b(+)	5'- GGGAATTCCATATGGCGCAGA AGAATCCGACAGTCG -3'	7
SPA-1	PSEU60	<i>Not</i> I	pET21b(+)	5'- ATAAGAATGCGGCCGCTGGCG TCCGCAGGGCGGT -3'	8
SPA-1	PSEU409	<i>Bgl</i> II	pCMV-GH	5'- GGGCAGATCTTGTATGGCGCAG AAGAATCCG-3'	9
SPA-1	PSEU410	<i>Xba</i> I	pCMV-GH	5'- GATCCTCTAGATTGGCGTCCG CAGGC GGTC-3'	10
SPA-2	PSEU47	<i>Nde</i> I	pET21b(+)	5'- GGGAATTCCATATGGGCTTCC AACTGCGCGG-3'	11
SPA-2	PSEU48	<i>Hind</i> III	pET21b(+)	5'- CGCCAAGCTTCGGGGTGGGA ACTCGAT-3'	12
SPA-2	PSEU411	<i>Bam</i> HI	pCMV-GH	5'- CGAGGATCCTATGTGCGGCTT CCA ACTGCG-3'	13
SPA-2	PSEU412	<i>Hind</i> III	pCMV-GH	5'- CAGAAGCTTCGGGGTGGGA CTCGATCGGC-3'	14
SPA-3	PSEU37	<i>Nde</i> I	pET21b(+)	5'- GGGAATTCCATATGAGCAGCA ACAGCAAGAAGGAACTC-3'	15

WO 03/042240

PCT/CA02/01740

SPA-3	PSEU38	<i>Hind</i> III	pET21b (+)	5'- CGCCAAGCTTGC GGATGGTGT AGGCGAC-3'	16
SPA-3	PSEU413	<i>Bam</i> HI	pCMV-GH	5'- CGAGGATCCTATGAGCAAGAA GGAACCTCCC-3'	17
SPA-3	PSEU414	<i>Hind</i> III	pCMV-GH	5'- CAGAAGCTTCTAGCGGATTGG TGTAGGCGAC-3'	18

It was determined that the open reading frame (ORF) which codes for SPA-1 polypeptide contains 1347 bp and encodes a 448 amino acid residues polypeptide with a predicted pI of 8.20 and a 5 predicted molecular mass of 47757.95 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO :2) using the Spscan software (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 32 amino acid residues signal peptide (MRNPERSALLKVSGLLGSTVVAMGLGLSSACA), 10 which ends with a cleavage site located between an alanine and a glutamine residues.

To confirm the presence by PCR amplification of SPA-1 (SEQ ID NO:1) gene, the following 5 distinct P. aeruginosa strains were 15 used: P. aeruginosa PA01, NF25, NF45, 1019-5 and B. Clinical isolates were provided by the Centre de Recherche en Infectiologie (Laval University, Québec, Canada). The E. coli XL1-Blue MRF' was used in these experiments as a negative control. SPA-1 (SEQ ID NO :1) gene was amplified by PCR (Hybaid 20 PCR Express, ESBE Scientific) from genomic DNA from the 5 P. aeruginosa strains, and the control E. coli strain using the oligonucleotides primers PSEU59 and PSEU60 (Table 1). PCR was performed with 10 cycles of 10 sec at 94°C, 30 sec at 45°C and 2 min at 68°C followed by 20 cycles of 10 sec at 94°C, 30 sec at 25 45°C and 2 min with 0.05 sec increments per cycle at 68°C and a final elongation period of 7 min at 68°C. The PCR products were size fractionated in 1% agarose gels and were visualized by ethidium bromide staining. The results of these PCR amplifications are presented in Table 2. The analysis of the 30 amplification products revealed that SPA-1 (SEQ ID NO :1) gene was present in the genome of all of the 5 P. aeruginosa strains

WO 03/042240

PCT/CA02/01740

tested. No such product was detected when the control E. coli DNA was submitted to identical PCR amplifications with these oligonucleotide primers.

5

Table 2. Identification of P. aeruginosa genes by PCR amplification.

Strain Identification	Identification by PCR amplification of		
	SPA-1	SPA-2	SPA-3
PAO1	+	+	+
NF25	+	+	+
NF45	+	+	+
1019-5	+	+	+
B	+	+	+
<u>E. coli</u>	-	-	-

10 EXAMPLE 2

This example illustrates the cloning and molecular characteristics of SPA-2 gene and corresponding polypeptide.

The coding region of P. aeruginosa SPA-2 (SEQ ID NO: 3) gene was 15 amplified by PCR (Hybaid PCR Express, ESBE Scientific) from genomic DNA of P. aeruginosa strain PAO1 using the following oligos that contained base extensions for the addition of restriction sites *Nde*I (CATATG) and *Hind*III (AAGCTT): PSEU47 and PSEU48, which are presented in Table 1. The methods used for 20 cloning SPA-2 gene into an expression vector and sequencing are similar to the methods described in Example 1.

It was determined that the open reading frame (ORF) which codes for SPA-2 contains 624 bp and encodes a 207 amino acid residues 25 polypeptide with a predicted pI of 5.04 and a predicted molecular mass of 22882.24 Da. Analysis of the predicted amino acid residues sequence (SEQ ID NO :4) using the Spscan software (Wisconsin Sequence Analysis Package; Genetics Computer Group)

WO 03/042240

PCT/CA02/01740

suggested the existence of a 19 amino acid residues signal peptide (MKRILTSAALIGMTLLAA), which ends with a cleavage site located between an alanine and a cysteine residues.

5 The SPA-2 gene was shown to be present after PCR amplification using the oligonucleotide primers PSEU47 and PSEU48 in the 5 P. aeruginosa strains tested (Table 2). The methods used for PCR amplification of the SPA-2 gene were similar to the methods presented in Example 1. No such product was detected when the 10 control E. coli DNA was submitted to identical PCR amplification with these oligonucleotide primers.

EXAMPLE 3

This example illustrates the cloning and molecular 15 characteristics of SPA-3 gene and corresponding polypeptide.

The coding region of P. aeruginosa SPA-3 (SEQ ID NO: 5) gene was amplified by PCR (Hybaid PCR Express, ESBE Scientific) from genomic DNA of P. aeruginosa strain PA01 using the following 20 oligos that contained base extensions for the addition of restriction sites *Nde*I (CATATG) and *Hind*III (AAGCTT): PSEU37 and PSEU38, which are presented in Table 1. The methods used for cloning SPA-3 gene into an expression vector and sequencing are similar to the methods described in Example 1.

25

It was determined that the open reading frame (ORF) which codes for SPA-3 contains 1143 bp and encodes a 380 amino acid residues polypeptide with a predicted pI of 5.15 and a predicted molecular mass of 40394.19 Da. Analysis of the predicted amino 30 acid residues sequence (SEQ ID NO :6) using the Spscan software (Wisconsin Sequence Analysis Package; Genetics Computer Group) suggested the existence of a 21 amino acid residues signal peptide (MVQWKHAALLALALAVVGCSS), which ends with a cleavage site located between a serine and an asparagine residues.

35

The SPA-3 gene was shown to be present after PCR amplification using the oligonucleotide primers PSEU37 and PSEU38 in the 5 P. aeruginosa strains tested (Table 2). The methods used for PCR amplification of the SPA-3 gene were similar to the methods

WO 03/042240

PCT/CA02/01740

presented in Example 1. No such product was detected when the control *E. coli* DNA was submitted to identical PCR amplification with these oligonucleotide primers.

5

EXAMPLE 4

This example illustrates the cloning of *P. aeruginosa* genes in CMV plasmid pCMV-GH.

10 The DNA coding regions of *P. aeruginosa* polypeptides were inserted in phase downstream of a human growth hormone (hGH) gene which was under the transcriptional control of the cytomegalovirus (CMV) promotor in the plasmid vector pCMV-GH (Tang et al., *Nature*, 1992, 356 :152). The CMV promotor is non-
15 functional in *E. coli* cells but active upon administration of the plasmid in eukaryotic cells. The vector also incorporated the ampicillin resistance gene.

The coding regions of SPA-1 (SEQ ID NO: 1), SPA-2 (SEQ ID NO: 3)
20 and SPA-3 (SEQ ID NO: 5) genes without their leader peptide regions were amplified by PCR (Hybaid PCR Express, ESBE Scientific) from genomic DNA of *P. aeruginosa* strain PAO1 using oligonucleotide primers that contained base extensions for the addition of restriction sites *Bam*HI (GGATCC), *Bgl*III (AGATCT),
25 *Xba*I (TCTAGA), or *Hind*III (AAGCTT) which are described in Table 1. The PCR products were purified from agarose gel using a QIAquick gel extraction kit (Qiagen), and digested with restriction enzymes (Amersham Pharmacia Biotech, Inc). The pCMV-GH vector (Laboratory of Dr. Stephen A. Johnston, Department of
30 Biochemistry, The University of Texas, Dallas, Texas) was digested with *Bam*HI, *Bgl*III, *Xba*I, or *Hind*III and purified from agarose gel using the QIAquick gel extraction kit (Qiagen). The digested DNA fragments were ligated to the digested pCMV-GH vector to create the hGH-SPA-1, hGH-SPA-2 and hGH-SPA-3 fusion
35 polypeptides under the control of the CMV promoter. The ligated products were transformed into *E. coli* strain DH5 α [ϕ 80dlacZ Δ M15 Δ (lacZYA-argF) U169 endA1 recA1 hsdR17(r_k-m_k+) deoR thi-1 supE44 λ -gyrA96 relA1] (Gibco BRL) according to the method of Simanis

WO 03/042240

PCT/CA02/01740

(Hanahan, D. DNA Cloning, 1985, D.M. Glover (ed), pp. 109-135). The recombinant pCMV plasmids were purified using a Qiagen kit, and the nucleotide sequences of the DNA inserts were verified by DNA sequencing.

5

EXAMPLE 5

This example illustrates the use of DNA to elicit an immune response to P. aeruginosa polypeptide antigens.

10

A group of 8 female BALB/c mice (Charles River, St-Constant, Québec, Canada) were immunized by intramuscular injection of 100 μ l three times at two- or three-week intervals with 50 μ g of recombinant pCMV-GH encoding SPA-1 (SEQ ID NO: 1), SPA-2 (SEQ ID NO: 3) and SPA-3 (SEQ ID NO: 5) genes in presence of 50 μ g of granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmid pCMV-GH-GM-CSF (Laboratory of Dr. Stephen A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas). As control, a group of mice were injected with 20 50 μ g of pCMV-GH in presence of 50 μ g of pCMV-GH-GM-CSF. Blood samples were collected from the orbital sinus prior to each immunization and seven days following the third injection. Serum antibody responses were determined by ELISA using the corresponding His-Tag labeled P. aeruginosa recombinant 25 polypeptides as coating antigen. The production and purification of these His-tag labeled P. aeruginosa recombinant polypeptides are presented in Example 6.

30 **EXAMPLE 6**

This example illustrates the production and purification of P. aeruginosa recombinant polypeptides.

The recombinant pET21b(+) plasmid with SPA-1 (SEQ ID NO: 1), 35 SPA-2 (SEQ ID NO: 3) and SPA-3 (SEQ ID NO: 5) genes were used to transform by electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Canada) E. coli strain Tuner (DE3) [F⁻ *ompT* *hsdS_b* (r_b m_b) *gal dcm lacY1* (DE3)] (Novagen). In this strain of E. coli, the T7 promotor controlling expression of the

WO 03/042240

PCT/CA02/01740

recombinant polypeptide is specifically recognized by the T7 RNA polymerase (present on the λ DE3 prophage) whose gene is under the control of the lac promotor which is inducible by isopropyl- β -d-thio-galactopyranoside (IPTG). The transformant Tuner(DE3)/5 rpET21 was grown at 37°C with agitation at 250 rpm in Luria-Betani (LB) broth (peptone 10g/L, yeast extract 5g/L, NaCl 10g/L) containing 100 μ g of ampicillin (Sigma-Aldrich Canada Ltd., Oakville, Canada) per ml until the A_{600} reached a value of 0.5. In order to induce the production of His-tagged *P.* 10 aerugionsa recombinant polypeptides, the cells were incubated for 3 additional hours in the presence of IPTG at a final concentration of 1 mM. Induced cells from a 1-L culture were pelleted by centrifugation and frozen at -70°C.

15 The purification of the recombinant polypeptides from the soluble or insoluble cytoplasmic fractions of IPTG-induced Tuner(DE3)/rpET21 was done by affinity chromatography based on the properties of the His•Tag sequence (6 consecutive histidine residues) to bind to divalent cations (Ni^{2+}) immobilized on the 20 His•Bind metal chelation resin. Briefly, for the purification of SPA-2 and SPA-3 polypeptides from the soluble cytoplasmic fraction, the pelleted cells obtained from a 1-L culture induced with IPTG were sonicated and centrifuged at 21,000 x g for 30 min to remove debris. For the purification of recombinant 25 polypeptides SPA-1 from the insoluble cytoplasmic fraction, the cells were sonicated and centrifuged as above and the resulting pellet was resuspended in lysis buffer (5 mM imidazole, 2 M NaCl, 20 mM Tris-HCl pH 7.9) with 6 M Guanidine-HCl. The suspension was incubated on ice for 1 h and centrifuged at 30 39,000 x g for 20 min. The supernatants containing soluble SPA-2 and SPA-3 polypeptides or solubilized SPA-1 polypeptide were deposited on a Ni-NTA agarose column (Qiagen). The His-tag labeled *P. aeruginosa* recombinant polypeptides were eluted with 250 mM imidazole-500mM NaCl-20 mM Tris pH 7.9. The removal of 35 the salt and imidazole from the sample was done by dialysis against PBS at 4°C. The quantities of recombinant polypeptides obtained from the soluble or insoluble fractions of *E. coli* was estimated by MicroBCA (Pierce, Rockford, Illinois).

EXAMPLE 7

This example illustrates the reactivity of the His-tagged *P. aeruginosa* recombinant polypeptides with antibodies present in human sera.

As shown in Table 3, SPA-1, SPA-2 and SPA-3 His-tagged recombinant polypeptides were recognized in immunoblots by the 10 antibodies present in the human sera. It indicates that humans, which are normally in contact with *P. aeruginosa*, do develop antibodies that are specific to these polypeptides. These particular human antibodies might be implicated in the protection against *P. aeruginosa* infection.

15

Table 3. Reactivity in immunoblots of antibodies present in human sera with *P. aeruginosa* His-tagged fusion recombinant polypeptides.

Purified recombinant polypeptide I.D. ¹	Apparent molecular weight (kDa) ²	Reactivity in immunoblots with antibodies present in human sera ³
SPA-1	48	+
SPA-2	25	+
SPA-3	40	+

20 ¹His-tagged recombinant polypeptides produced and purified as described in Example 6 were used to perform the immunoblots.

²Molecular weight of the His-tagged recombinant polypeptide was estimated after SDS-PAGE.

³A pool of three human sera, each diluted 1/500, was prepared in 25 order to perform the immunoblots.

EXAMPLE 8

This example illustrates the accessibility to antibodies of the 30 SPA-1, SPA-2 and SPA-3 polypeptides at the surface of *P. aeruginosa* strain.

WO 03/042240

PCT/CA02/01740

Bacteria were grown overnight on blood agar at 30°C. Colonies were resuspended in LB broth to obtain an O.D._{600nm} of 0.3. Dilutions of anti-SPA-1, anti-SPA-2 or anti-SPA-3 or control sera were then added and allowed to bind to the cells, which 5 were incubated for 2 h at 4°C with rotation. Samples were washed 2 times in blocking buffer [phosphate-buffered saline (PBS) containing 2% bovine serum albumin (BSA)], and then 500 µl of goat fluorescein (FITC)-conjugated anti-mouse IgG Fc (gamma) fragment-specific, diluted in blocking buffer, was added. After 10 an additional incubation of 2 h at 4°C with rotation in the dark, samples were washed 2 times in blocking buffer and fixed with 0.25 % formaldehyde in PBS buffer for 18 h at 4°C. Cells were centrifuged and resuspended in 0.5 ml of PBS buffer. Cells were kept in the dark at 4°C until analyzed by flow cytometry 15 (Epics® XL; Beckman Coulter, Inc.). Flow cytometric analysis revealed that SPA-1-, SPA-2-, and SPA-3-specific antibodies efficiently recognized their corresponding surface-exposed epitopes on the homologous (PA01) P. aeruginosa strain tested (Table 4). It was determined that more than 55 % of the 10,000 20 Pseudomonas cells analyzed were labeled with the antibodies present in the SPA-1-, SPA-2-, and SPA-3-specific sera. These observations clearly demonstrate that the SPA-1, SPA-2 and SPA-3 polypeptides are accessible at the surface, where they can be easily recognized by antibodies. Anti-P. aeruginosa antibodies 25 were shown to play an important role in the protection against P. aeruginosa infection.

Table 4. Evaluation of the attachment of SPA-1-, SPA-2- and 30 SPA-3-specific antibodies at the surface of intact cells of P. aeruginosa strain PA01.

Serum Identification	Fluorescence Index ²	% of labeled cells ³
SPA-1-specific sera ¹	10.0	58
SPA-2-specific sera	21.3	75
SPA-3-specific sera	10.0	55
Negative control sera ⁴	1.0	1.0

WO 03/042240

PCT/CA02/01740

Positive control serum ⁵	37.4	83
-------------------------------------	------	----

¹ Mice were injected subcutaneously four times at two-week intervals with 20 μ g of purified recombinant polypeptides mixed with 10 μ g of QuilA adjuvant (Cedarlane Laboratories, Hornby, 5 Canada). Sera were diluted 1/50.

² The fluorescence index was calculated as the median fluorescence value obtained after labeling the cells with an immune serum divided by the fluorescence value obtained for a control mouse serum. A fluorescence value of 1 indicated that 10 there was no binding of antibodies at the surface of intact Pseudomonas cells.

³ % of labeled cells out of the 10,000 cells analyzed.

⁴ Sera collected from unimmunized or sham-immunized mice were pooled, diluted 1/50, and used as negative controls for this 15 assay.

⁵ Serum obtained from a mouse immunized with 20 μ g of purified recombinant outer membrane polypeptide OprI from P. aeruginosa strain PAO1 was diluted 1/50 and used as a positive control for the assay.

20

EXAMPLE 9

This example illustrates the protection of mice against P. aeruginosa infection induced by immunization with SPA-2 25 recombinant polypeptide.

Groups of 4 female BALB/c mice (Charles River) were immunized subcutaneously four times at two-week intervals with 20 μ g of affinity purified His-tagged P. aeruginosa SPA-2 recombinant 30 polypeptide in presence of 10% of QuilA adjuvant (Cedarlane Laboratories Ltd) or, as control, with QuilA adjuvant alone in PBS. Blood samples were collected from the orbital sinus on day 0, 14, 28, and 42 prior to each immunization and 7 days (day 49) following the fourth injection. One week later, the mice were 35 challenged intratrachealy with approximately 5×10^7 CFU of P. aeruginosa strain PAO1. Samples of the P. aeruginosa challenge inoculum were plated on blood agar plates to determine the CFU and to verify the challenge dose. Mice survival was monitored

WO 03/042240

PCT/CA02/01740

on a 5-day period and protection was reported as the percentage of surviving mice compared to survival in the group of mice immunized with adjuvant only. Results reported in Table 5 indicate that immunization with SPA-2 recombinant polypeptide 5 can delay mortality and protect mice from a lethal Pseudomonas infection.

Table 5. Protection conferred by immunization with SPA-2 recombinant polypeptide against an intratracheal lethal challenge.

Groups ¹	% Survival	Mean Survival Time
SPA-2	75	108 h
QuilA	25	75 h

10

¹ Mice were injected subcutaneously four times at two-week intervals with 20 µg of purified recombinant polypeptide mixed with 10 µg of QuilA adjuvant (Cedarlane Laboratories, Hornby, Canada); or with QuilA adjuvant only as a negative control.

15

Example 10. This example illustrates the identification of SPA-1 homologs, in the *Pseudomonas aeruginosa* genome, which can be used as immunogens for vaccines.

20

Genome analysis allowed the identification of 3 genes coding for proteins homologous to SPA-1. The sequences of each gene and protein are presented in Figures 7, 9, 11 and Figures 8, 10, 12 respectively. SHB-PA104 (SEQ ID No: 8), SHB-PA105 (SEQ ID No: 25 10) and SHB-PA106 (SEQ ID No: 12) proteins present 49.4 % (over 389 aa; Figure 13), 33.2 % (over 361 aa; Figure 14) and 32.2 % (over 289 aa; Figure 15) identity with SPA-1 protein (448 aa) respectively. A paper presenting the 4 homologous proteins was published in January 2002 (Blackburn, N.T. and Clarke, A.J. 30 (2002) Biochemistry, 41: 1001-1013). The paper describes these proteins as a family of lytic transglycosylases. Due to homologies with SPA-1, they may represent interesting, accessible vaccine candidates. Table 6 describes primers to amplify the three novel genes that can be overexpressed, 35 purified and used as immunogens as for SPA-1.

Table 6. Oligonucleotide primers for PCR amplification of new P. aeruginosa genes.

Genes	Primers I.D.	Restriction site	Vector	Sequence	Sequence I.D. No.
SHB-PA104	PSEU446	<i>Nde</i> I	pET19b	5'- GAGTTCCATATGA GCTTCCCTTCCTG CCTCGCCGGCCTG CAG -3'	25
SHB-PA104	PSEU622	<i>Bam</i> HI	pET19b	5'- CGCTGAGGATCCT CACTTCTGCAATT GCTTGCGCTCGAG CC -3'	26
SHB-PA105	PSEU442	<i>Nde</i> I	pET19b	5'- GGGAATTCCATAT GGGGGCGGCCAG GCGG CG-3'	27
SHB-PA105	PSEU443	<i>Bam</i> HI	pET19b	5'- GCGCTGAGGATCC TCAATGGGCACCT CGCG -3'	28
SHB-PA106	PSEU438	<i>Nde</i> I	pET19b	5'- GGGAATTCCATAT GAGCAGCGAACCG ACGC -3'	29
SHB-PA106	PSEU638	<i>Hind</i> III	pET19b	5'- CGCCAAGCTTCTA ATCCTGCCTGACG ACGG -3'	30

5 Example 11. This example illustrates the method used for extracting lipids from bacterial cells.

Complex lipid mixtures were extracted from E. coli in order to generate liposome formulations from bacterial origin. To 10 generate such complex lipid mixtures other bacterial species would have also been suitable such as: Neisseria spp, Haemophilus spp, Pseudomonas spp, bacteriodes spp, Legionella spp, Vibrio spp, Brucella spp, Bordetella spp, Campylobacter spp, Klebsiella spp, Salmonella spp, Shigella spp, Proteus spp,

WO 03/042240

PCT/CA02/01740

and Yersinia spp. Other species could also be used. The following method was used to generate the complex lipid mixtures used to generate the liposome formulations presented in Example 12.

5

Bacteria were grown overnight in BHI broth at 37°C in presence of 8% CO₂ (175 rpm). Cells were collected by centrifugation and the pellet was suspended in 6.7 ml of methanol per gram of cells (wet weight). This bacterial suspension was sonicated in an ice 10 bath twice using a Sonic dismembrator 500 (Fisher Scientific) with a microtip probe adjusted at 8. This suspension was then heated at 65°C for 30 min. After this incubation period, 2 volumes of chloroform were added to the suspension and agitated for 1 h at room temperature. The suspension was filtered through 15 Whatman No. 4 filter. The filtrate was transferred in a Teflon tube and 0.2 volume of saline solution (NaCl 0.6% (w/v)) was then added. After centrifugation, the upper phase and the precipitate at the interface were discarded. The lower phase was extracted with one volume of chloroform:methanol:saline solution 20 (3:48:47) at least four times or until there was no more precipitate at the interface. After the final extraction, the lower organic phase was dried in a rotatory evaporator (Rotavapor, Büchi, Switzerland). The dried phospholipids were stored at -80°C or resuspended in a solution of 25 chloroform:methanol (2:1).

Example 12. This example illustrates the incorporation of recombinant SPA-1 into different liposome formulations.

30 Liposomes were prepared using a dialysis method. Liposomes were prepared with different synthetic (see list 1 in this Example; Other lipids can be used and are described in Remington's on Pharmaceutical Sciences, 18th ed., 1990, Mack Publishing Co., Pennsylvania, p.390.) or bacterial phospholipids and/or 35 cholesterol, which were combined at different ratios. Some liposome formulation were also prepared with the adjuvant monophosphoryl lipid A (MPLA, Avanti polar lipids, Alabaster, AL) at 600 µg/ml. SPA-1 protein was first precipitated in 90%

WO 03/042240

PCT/CA02/01740

ethanol (vol/vol) and denatured in 1 ml of PBS buffer containing 1% (wt/vol) of SDS (Sigma chemical) in PBS buffer, and heated at 100°C for 10 min. The solution was diluted with 1 ml of PBS buffer containing 15% (wt/vol) of n-octyl β-D-glucopyranoside 5 (OG, Sigma) and incubated at room temperature for 3 h. Lipids were dissolved in a chloroform:methanol solution (2:1) in a round bottom glass flask and dried using a rotatory evaporator (Rotavapor, Büchi, Switzerland) to achieve an even film on the vessel. The above protein-detergent solution was then added to 10 the lipid film and mixed gently until the film was dissolved. The solution after mixing was slightly opalescent in appearance. The solution was then extensively dialysed against PBS buffer (pH 7.4) to remove detergent and to induce liposome formation. After dialysis, the resulting milky solution was sequentially 15 extruded through 1000, 400, 200, and 100 nm polycarbonate filters using a stainless steel extrusion device (Lipex Biomembranes, Vancouver, Canada). The unencapsulated proteins were removed by ultracentrifugation at 25 0000 x g for 1 h at 4°C. The pellet was suspended with PBS buffer containing 0.3 M 20 of sucrose. Vesicle size and homogeneity were evaluated by quasi-elastic light scattering with a submicron particles analyzer (model N4 Plus, Beckman Coulter). Using this apparatus, it was estimated that the liposome size in the different preparations was approximately 100 nm. All liposome preparations 25 were sterilized by filtration through a 0.22-μm membrane and stored at -80°C until used. The amount of recombinant protein incorporated in the liposome was estimated by MicroBCA (Pierce, Rockford, Ill.) after phospholipid extraction of SPA-1-liposome preparations with chloroform:methanol solution (2:1) as 30 described by Wessel and Flügge (Anal. Biochem. 1984, 138:141-143).

Gel filtration was used as an alternate method to induce the formation of SPA-1 liposome from the SPA-1-OG-SDS-lipids mixed 35 micellar solution and to remove detergents. The SPA-1-OG-SDS-lipids solution was applied directly on top of a Sephadex G-50 (column size: 2 x 20cm, Pharmacia) or a P-6 (column size: 2 x 20cm, Bio Rad) size exclusion chromatography/desalting column and eluted with PBS buffer at a flow rate of 2.5 ml/min.

WO 03/042240

PCT/CA02/01740

Fractions containing both protein and lipids were pooled, extruded, centrifuged, and the vesicle sizes were evaluated as described above. All preparations were sterilized through a 0.22- μ m membrane and stored at -80°C until used.

5

List 1. Partial list of synthetic lipids used to prepare SPA-1-liposome preparations.

1,2-Dilauroyl-*sn*-Glycero-3-Phosphate (DLPA), Dimyristoyl-*sn*-10 Glycero-3-Phosphate (DMPA), 1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphate (DPPA), 1,2-Distearoyl-*sn*-Glycero-3-Phosphate (DSPA), 1,2-Dioleoyl-*sn*-Glycero-3-Phosphate (DOPA), 1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphate (POPA), 1,2-Dilauroyl-*sn*-Glycero-3-Phosphocholine (DLPC), 1,2-Ditridodecanoyl-*sn*-Glycero-3-15 Phosphocholine, 1,2-Dimyristoyl-*sn*-Glycero-3-Phosphocholine (DMPC), 1,2-Dipentadecanoyl-*sn*-Glycero-3-Phosphocholine, 1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphocholine (DPPC), 1,2-Diheptadecanoyl-*sn*-Glycero-3-Phosphocholine, 1,2-Distearoyl-*sn*-Glycero-3-Phosphocholine (DSPC), 1,2-Dimyristoleoyl-*sn*-Glycero-20 3-Phosphocholine, 1,2-Dipalmitoleoyl-*sn*-Glycero-3-Phosphocholine, 1,2-Dioleoyl-*sn*-Glycero-3-Phosphocholine (DOPC), 1-Myristoyl-2-Palmitoyl-*sn*-Glycero-3-Phosphocholine, 1-Myristoyl-2-Stearoyl-*sn*-Glycero-3-Phosphocholine, 1-Palmitoyl-2-Myristoyl-*sn*-Glycero-3-Phosphocholine, 1-Palmitoyl-2-Stearoyl-25 3-*sn*-Glycero-3-Phosphocholine, 1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphocholine (POPC), 1-Palmitoyl-2-Linoleoyl-*sn*-Glycero-3-Phosphocholine, 1,2-Dilauroyl-*sn*-Glycero-3-Phosphoethanolamine (DLPE), 1,2-Dimyristoyl-*sn*-Glycero-3-Phosphoethanolamine (DMPE), 1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphoethanolamine (DPPE), 1,2-30 Dipalmitoleoyl-*sn*-Glycero-3-Phosphoethanolamine, 1,2-Distearoyl-*sn*-Glycero-3-Phosphoethanolamine (DSPE), 1,2-Dioleoyl-*sn*-Glycero-3-Phosphoethanolamine (DOPE), 1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphoethanolamine (POPE), 1,2-Dilauroyl-*sn*-Glycero-3-[Phospho-RAC-(1-glycerol)] (DLPG), 1,2-Dimyristoyl-*sn*-Glycero-35 3-[Phospho-RAC-(1-glycerol)] (DMPG), 1,2-Dipalmitoyl-*sn*-Glycero-3-[Phospho-RAC-(1-glycerol)] (DPPG), 1,2-Distearoyl-*sn*-Glycero-3-[Phospho-RAC-(1-glycerol)] (DSPG), 1,2-Dioleoyl-*sn*-Glycero-3-[Phospho-RAC-(1-glycerol)] (DOPG), 1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-[Phospho-RAC-(1-glycerol)] (POPG), 1,2-Dilauroyl-*sn*-

WO 03/042240

PCT/CA02/01740

Glycero-3-[Phospho-L-Serine] (DLPS), 1,2-Dimyristoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DMPS), 1,2-Dipalmitoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DPPS), 1,2-Distearoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DSPS), 1,2-Dioleoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DOPS), 1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-[Phospho-L-Serine] (POPS).

Example 13. This example illustrates the immunization of mice 10 and rabbits with SPA-1-liposome formulations.

Groups of female BALB/c mice (Charles River Laboratories, St-Constant, Quebec, Canada) were immunized intramuscularly (IM) four times at two-week intervals with 20 µg of recombinant SPA-1 15 incorporated into different liposome preparations or, as control, with protein-free liposome formulations. Blood samples were collected from the orbital sinus prior to each immunization and two weeks after the last injection. The serum samples were stored at -20°C.

20

New Zealand White female rabbits (2.5Kg, Charles River) were immunized IM three or four times at three-week intervals at several sites with 100 µg of recombinant SPA-1 protein incorporated in different liposome formulations. Serum samples 25 were collected before each immunization and three weeks after the last injection. The serum samples were stored at -20°C.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME 1 DE 2

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME 1 OF 2

NOTE: For additional volumes please contact the Canadian Patent Office.

69140-205D

CLAIMS:

1. A chimeric polypeptide comprising two or more antigenic polypeptide fragments wherein each of the two or more antigenic polypeptide fragments comprises at least 15 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:2, provided that the two or more antigenic polypeptide fragments are linked to form a chimeric polypeptide, wherein the chimeric polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.
2. A pharmaceutical composition comprising the chimeric polypeptide according to claim 1 and a pharmaceutically acceptable carrier, diluent, adjuvant, or liposome.
3. A pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) an isolated polypeptide comprising (i) an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:2, or (ii) an amino acid sequence at least 90% identical to the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2,
wherein the isolated polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.
4. The pharmaceutical composition of claim 3, wherein the isolated polypeptide comprises (i) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:2 or (ii) an amino acid sequence at least 95%

69140-205D

identical to the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2.

5. The pharmaceutical composition of claim 3, wherein the isolated polypeptide comprises (a) the amino acid sequence 5 set forth in SEQ ID NO:2 or (b) the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an isolated polypeptide comprising an antigenic fragment, wherein the 10 antigenic fragment comprises at least 15 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:2, and wherein the antigenic fragment is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.

15 7. The pharmaceutical composition according to any one of claims 3-6, wherein the isolated polypeptide is conjugated or coupled to a carrier protein.

8. The pharmaceutical composition according to claim 7, wherein the carrier protein is a bacterial protein.

20 9. The pharmaceutical composition according to any one of claims 3-8 further comprising a pharmaceutically acceptable adjuvant.

10. The pharmaceutical composition according to any one of claims 3-9, wherein the isolated polypeptide is associated 25 with a liposome.

11. The pharmaceutical composition according to any one of claims 3-8, wherein the isolated polypeptide is produced

69140-205D

recombinantly by a method comprising culturing a host cell transfected with a vector that comprises a polynucleotide encoding the isolated polypeptide, wherein the polynucleotide is operably linked to an expression control region.

5 12. The pharmaceutical composition according to any one of claims 2-11 for use in inducing an immune response to the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.

10 13. Use of the pharmaceutical composition according to any one of claims 2-11 for inducing an immune response to the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.

15 14. An antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2 for use in the prophylactic or therapeutic treatment of a *Pseudomonas aeruginosa* infection.

20 15. Use of an antibody, or antigen-binding fragment thereof, for the prophylactic or therapeutic treatment of a *Pseudomonas aeruginosa* infection, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.

16. A method for detecting *Pseudomonas aeruginosa* in a biological sample comprising:

25 (a) incubating the biological sample with an isolated polypeptide selected from

69140-205D

(i) an isolated polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:2;

5 (ii) an isolated polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2;

(iii) an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:2;

10 (iv) an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2;

(v) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2;

15 (vi) an isolated polypeptide comprising the amino acid sequence set forth from amino acid 33 to amino acid 448 of SEQ ID NO:2; and

20 (vii) an isolated polypeptide comprising an antigenic fragment wherein the fragment comprises at least 15 contiguous amino acids of the amino acid sequence set forth in SEQ ID NO:2,

25 wherein the isolated polypeptide is capable of eliciting antibodies that specifically bind to a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2; and

69140-205D

(b) detecting specifically bound polypeptide which indicates the presence of antibody specific to *Pseudomonas aeruginosa* in the biological sample.

17. A method for detecting *Pseudomonas aeruginosa* in a
5 biological sample comprising:

(a) incubating the biological sample with an isolated antibody or antigen-binding fragment thereof that specifically binds to a *Pseudomonas aeruginosa* polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2; and

10 (b) detecting specifically bound antibody, or antigen-binding fragment thereof, to the polypeptide, which indicates the presence of *Pseudomonas aeruginosa* in the biological sample.

WO 03/042240

PCT/CA02/01740

Figure 1 (SEQ ID NO: 1)

```

1 ATGCGTAACC CGAACGATC CGCCCTGCTG AAGGTGAGCG GGCTGCTGGG CAGCACCGTC
61 GTCGCATGG GGCTTGGCCT CTCCAGCGCC TGCAGCAGA AGAATCCGAC AGTCGAATAC
121 AACCAGCTG CCGCTCCCT GCAGACCAAG GCGCCCTTCT CCGGGCGCCGG CCCGGCCGCC
181 TCGGTGCCCG CTGGCGCGCC GAACGAGGCC CAGCCTGGGC AAAGCTTCGA ACAGTGGCGC
241 GACGCCTTCC GTCAACAGGC GCTGGCCGGT GGAATCGATG CGCAGACCTT CGATCGCGCC
301 TTCGCCGGCG TCCAGCCCAGA TCCCAGCCGTG GTCGAAGCAG ACCGCAGCCA GCCGGAATTG
361 ACCCGACCGG TATGGAAGTA CCTGGAAGGC GCCCTCGATC CGCTGCGCGT TCGCCAGGGC
421 CAGGCGCGCC TGGCGCAGCA TGCGCGCATC CTCGGCGAAG TCGACGCGCG CCGATCGCGC
481 GATGCGGATG CGGTGGTGGC GATCTGGGGC ATGGAGAGCA ACTACGGTTC GCACATGGGC
541 AACAAAGAACG TGATCCGCTC CCTGGCGACC CTCGCCTATG AAGGACGCCG CCCGGAAATTG
601 GCCCCACGCC AGTTGCTCGC CGCCCTGAAG ATTCTCCAGC ACGGGCAGCT TCCGGCCTCC
661 TTCATGATCG GCTCCTGGGC CGGCGCCATG GGCCAGACCC AGTTCATCCC GACCACCCAC
721 AACCAAGTATG CGGTGGACTT CGACGGCGAC GGCAAGCGTG ACATCTGGGG CTCGCCCGGC
781 GACGCCCTGG CCTCCACCAGC CAACTACCTG AAAGCCTCCG GCTGGATCGC CGGACAACCC
841 TGGGGTTTCG AAGTCCGCCT GCCGGCAGGC TTCGACTATT CCCTGGCGGA ACTCACCATC
901 CGCAAGCCCC TGGGCGAATG GCAAGGGATG GCGTACAAG GCGTCAACGG CGGCCCCCTG
961 CCCTCCGGAC TCTCCGGCGA ACAGGGCTCG CTGCTGCTGC CGGCGGGCA CGCGGGCCCG
1021 GCCTTCCTGG TGCTGCACAA CTTCCCGCGCC ATCCTCAAGT ACAACAACTC CAGCGCCTAC
1081 GCCCTGGCCG TCGGCCTGCT CGCCGACAGC TTCAAGGGCG GCGGGCGGAT AGTCGGCGCC
1141 TGGCCGCTGG AGGATGTTCC GCTGAGCGC TCGCAGCGCA TCGAGCTGCA ACGGCAACTG
1201 GCCGCCCGCG GACACGATCC GGGCGCGGTG GATGGCATCA TCGGCGCCAA TACGCGCAAG
1261 GCGATCCGCG CCGCCAGCA GGAGTTCCGG TGGCCGGCGG ACGGCTATCC GACCCGGCG
1321 CTGCTCGACC GCCTGGGAC GCCATAG

```

Figure 2 (SEQ ID NO: 2)

```

1 MRNPERSALL KVSGLLGSTV VAMGLGLSSA CAQKNPTVEY NQPAAPLQTK APFSGAGPAA
61 SVPAGAPNEA QPGQSFEQWR DAFRQQALAG GIDAQTFDRA FAGVQPDPAV VEADRSQPEF
121 TRPVWKYLEG ALDPLRVRQG QARLAQHARI LGEVDARYAV DADAVVAIWG MESNYGSHMG
181 NKNVIRSLAT LAYEGRRPEF AHAQLLAALK ILQHGDVPAS FMIGSWAGAM GQTQFIPPTH
241 NQYAVDFDGD GKRDIGSPG DALASTANYL KASGWIAGQP WGFEVRLPAG FDYSLAELTI
301 RKPLGEWQGM GVQGVNGGPL PSGLSGEQAS LLLPAGHRGP AFLVLHNFRA ILKYNNSSAY
361 ALAVGLLADS FKGGGRIVGA WPLEDVPLSR SQRIELQRQL AARGHDPGAV DGIIGANTRK
421 AIRACQQEFG WPADGYPTPA LLDRLRTP*

```

Figure 3 (SEQ ID NO: 3)

```

1 ATGAAACGTA TCCTGACCAG CGCCGCGCTG ATCGGTATGA CCACCCCTGCT GGCCGCCTGC
61 GGCTTCCAAC TGCGCGCCT GGGCGATGCG CAATTGCGCG TCAAGGAAAT CGACGTGTCC
121 GCGCGCAACG CCTACGGCCC GACCGTGCAGC GAACTGAAGG AAACCCCTGGA AAACAGCGGC
181 GTGAAGGTCA CCAGCAACGC GCCCTACCAC CTGGTGCTGG TCCGCGAGGA CAACCAGCAG
241 CGCACCGTCA GCTACACCAG TTCCGCGCGC GGCAGGGAGT TCGAGCTGAC CAACACGATC
301 AACTACGAGA TCGTCGGCGC CAACGACCTG GTCTGATGA GCAACCAGGT ACAGGTGCAG
361 AAGGTCTACG TGCACGACGA AAACAACCTG ATCGGTTCCG ACCAGGAAGC CGCGCAGCTG
421 CGCAGCGAGA TGCAGCGCGA CCTGATCCAG CAGTTGTCCA TGCGCCTCCA GGCGCTGACC
481 CCGCGCAAC TCGACGAAGC CCAGCGCCAG GCAGAAGCCA AGGCCAAGGC GGAAGCCGAA
541 GCCCTGCGCG CCGCCGACGA GGCAGGGAGC CAGCGCCCGC CCGCCGAGCC GCAGCAGTCG
601 CCGATCGAGT TCCCCACCCCC GTGA

```

Figure 4 (SEQ ID NO: 4)

```

1 MKRILTSAAAL IGMTTLLAAC GFQLRGLGDA QFALKEIDVS ARNAYGPTVR ELKETLENSG
61 VKVTSNAPYH LVLVREDNQQ RTVSYTGSAR GAEFELNTI NYEIVGANDL VLMSNQVQVQ
121 KVYVHDENNLL IGSDQEAAQL RSEMRRDLIQ QLSMRLQALT PAQLDEAQRQ AEAKAKAEAE
181 ALRAADEAER QRRAAEPPQS PIEFPTP*

```

Figure 5 (SEQ ID NO: 5)

```

1 ATGGTGCAAT GGAAACACGC GGCGCTGCTC GCCCTGGCCC TGGCGGTCGT GGGTTGCAGC
61 AGCAACAGCA AGAAGGAAC CCCGCCCCGC GAACTGACCG ACTTCAAAGA GGAAGTCGTG
121 TTGAGCAAGC AGTGGAGCCG CTCGGTCGGT GATGGTCAGG GCGACCTGTA CAACCTGCTC
181 GAACCGGCCG TCGATGGTC CACCATCTAC GCCGCGTCCG CCGAAGGGCG GGTGATGGCG
241 ATCCAGCGCG AGACCGCGA CGTGCCTCTGG AAGAAGGACC TGGAACGTCC GGTTTCCGGC
301 GGTGTCGGCG TTGGCTACGG CCTGGTGCCTG GTGGGTACCC TGCGCGGTGA CGTGATCGCC
361 CTCGACGAAG CCACCGGCAA GAAGAAGTGG ACCAAGCGAG TCAACAGCGA AGTGCTGTGCG
421 GCGCCGGCCA CCAATGGCGA CGTGGTGGTG GTGCAGACCC AGGACGACAA GCTGATCGGC
481 CTCGATGCGG CCAGCGCGA CCAGCGCTGG ATCTACGAAA GCACCGTGCC GGTGCTGACC
541 CTGCGCGCA CGGGCGCGCC GCTGATTGCC GGCAACATGG CCCTGGCTGG CCTGGCCAGC
601 GGCAAGGTAG TGGCGGTGCGA CGTACAGCGC GGCGCTGCCA TCTGGGAGCA GCGGGTAGCG
661 ATTCCCCAGG GGCCTTCCGA ACTGGATCGC GTGGTGGACA TCGACGGCGG CCTCCCTGCTG
721 TCCGGCGACA CCCTCTACGT GGTCAGCTAC CAGGGCCGTG CCGCGGCGCT GGACGTGAAC
781 AGCGGGCGCC TGCTCTGGCA GCGCGAAGCG TCGAGCTACG TCGCGTGC CGAAGGCTTC
841 GGCAATATCT ACgtcAGCCA GGCCAGCGGT TCGGTGGAAG GCCTGGACTC GCGCGGCGCT
901 TCTTCGCTGT GGAACAACGA CGCCCTGGCG CGTCGCCAAC TGTCGGCTCC GGCGGTGTTC
961 TCCAGCAACG TGGTGGTCGG CGACCTGGAA GGCTACGTGC ACCTGCTGAG CCAGGTGGAC
1021 GGTCGCTTCG TCGGTGCGA GCGGGTCGAC AGCGATGGCG TGCGGGTTCG TCCGCTGGTG
1081 GTCGGGAGCT GGATGTACGT GTTCGGCAAC GGTGGCAAGC TCGTCGCCTA CACCATCCGC
1141 TAG

```

Figure 6 (SEQ ID NO: 6)

```

1 MVQWKHAALL ALALAVVGCS SNSKKELPPA ELTDFKEEVV LSKQWSRSVG DGQGDLYNLL
61 EPAVDGSTIY AASAEGRVMA IQRETGDVLW KKDLERPVSG GVGVGYGLVL VGTLRGDVIA
121 LDEATGKKKW TKRVNSEVLS APATNGDVV VQTQDDKLIG LDAASGDQRW IYESTVPVLT
181 LRGTAGPLIA GNMALAGLAS GKVVAVDVQR GLPIWEQRVA IPQGRSELDL VVDIDGGLLL
241 SGDTLYVVSY QGRAAAALDVN SGRLLWQREA SSYVGVAEGF GNIYVSQASG SVEGLDSRGA
301 SSLWNNDALA RRQLSAPAVF SSNVVVGDE GYVHLLSQVD GRFVGRERVD SDGVRVRPLV
361 VGSWMYVFGN GGKLVAYTIR*

```

Figure 7 (SEQ ID NO: 19)

```

1 ATGCGCAGCC TTCTTCTCTC CTCGCTGGCC CTGCTACCCG CCCTGGCCCT GGCGCAACCC
61 GACGCCTCGA GCTTCCTTC CTGCCTCGCC GGCCTGCAGA AGAAGGCCA GGCGCAGGGC
121 ATTTCCGCCG ACAGTTATGA GCGCTTCACC AGCGGCCTGC AGGCCGACCT CAGCGTGCTC
181 GACCTGCTCG ACGCGCAGCC GGAGTTACCC ACCCCGCTGT GGGACTACCT GGCCGGCCTG
241 GTGGACGAGC AGCGGGTCAG CGATGGCAAG GCGATGCTCG CCCAGCACGA CAAGCTGCTC
301 GACCAGGTGG CCGCGCGCTA CGGCGTGGAC AAGTACACGG TGGTGGCGGT GTGGGGCGTG
361 GAAAGCGACT ACGGGGCGAT CTTCGGAAG CGTCCGCTGC TGACCTCGCT GTCGACCCCTG
421 TCCTGCTACG GGCGCCGCCA GTCTTCTTC CAGGGCGAGT TCCTCGCCAC CCTGAAGCTG
481 TTGCAGGCCG GCGACATCCG CGACGCCGGC ATCACCGGCT CCTGGGCCGG GGCCCTCGGC
541 CATAACCAGT TCATGCCATC GACCTACCGC CGGATCGCCG TGGACTTCGA CGGGCACGGT
601 CGCCCGGACC TGGTAGGCAG CGTCCGGAT GCCCTCGGTT CCACCGCCAA CTACTGAAG
661 AAGGCTGGCT GGCACACGGG ACAGCCGTGG GGCTATGAAG TGAAGGTGCC GGCCTACTTC
721 CCCGCCAGCC TGGCCGGCG CGGCAAGCGC CAGCCGCTGT CGGCCTGGGT CGCCCGTGGG
781 GTGAGGCAGGG TCGACGGCCA GCGCTGCCG GGCAGCGACG AGAAGGCCG GATCCTCCTG
841 CCCAGGGCCC GGCCTTCTG GTCTATCGCA ACTACGATGC GATCTATTCC
901 TACAACGCCG CGGAAAGCTA CGCGCTGGCC ATCGCCCTGC TTTCCGACCG CCTGCGCGGC
961 GGCAGCGGCC TGGTGGCGTC CTGGCCGACC GACGACCCGG GCATCAGCGC GCTCGAGCGC
1021 AAGCAATTGC AGAAGGCAGT GCTGGCGCGC GGCTACGACA TCGCGAGGC CGACGGGCTG
1081 ATCGGCACCA GCACCGCGAA GGCGATCCAG GCCGAGCAGA AGCGCCTCGG CCTGACCCCG
1141 GCCGACGGTC GCGCCGGCG CAAGATCTC GAGGCGCTGA AGGGCGCCCA GCCCTGA

```

Figure 8 (SEQ ID NO: 20)

```

1 MRSLLLSSLA LLPALALAQP DASSFPSCLA GLQKKAQAOQ ISADSYERFT SGLQADLSVL
61 DLLDAOPEFT TPLWDYLAGL VDEQRVSDGK AMLAQHDKLL DQVAARYGVD KYTVVAWGV
121 ESDYGRIFGK RPLLTSLSTL SCYGRRQSFF QGEFLATLKL LQAGDIRDAG ITGSWAGAFG

```

WO 03/042240

PCT/CA02/01740

181 HTQFMPSTYA RIAVDFDGDG RRDLVGSVPD ALGSTANYLK KAGWRTGQPW GYEVKVPADF
 241 PASLAGRGKR QPLSAWVARG VRRVDGQPLP GGDEKAAILL PAGAQGPAFL VYRNYDAIYS
 301 YNAAESYALA IALLSDRLRG GSGLVASWPT DDPGISRLER KQLQKALLAR GYDGEADGL
 361 IGTSTRKAIQ AEQKRLGLTP ADGRAGRKIL EALKGAQP*

Figure 9 (SEQ ID NO: 21)

1 GTGAAGAACG CAATGCAAGT ACTGCGTACA TGGGCGGCCA GGGCGTCCA ATGGGTCGGC
 61 GTAGCCGGCG TCATTGGCCT GTCCGGGGCG GCCCAGGCGG GGGACTACGA CGGCTCGCCG
 121 CAAGTGGCCG AGTCGTCAG CGAAATGACC CGCGACTACG GCTTCGCCGG AGAGCAGCTG
 181 ATGGGGCTGT TCCCGCAGCT GAACCGCAAG CAGTCGATCC TCGATGCGAT CTCGCGCCCG
 241 GCCGAGCGGG TCAAGCAGTG GAAGGAATAAC CGGCCGATCT TCATCAGCGA CGCGCGCATC
 301 AGTCGTGGCG TCGACTTCTG GAACAAGCAT GCCGAAGACC TGGCGCGGGC GGAGAAGGAA
 361 TACGGCGTGC CGGCCGAGAT CATCGTCTCG ATCATCGGCG TGGAAACCTT CTTCGGCCGC
 421 AACACCGGCA GTTACCGGGT GATGGACGCG CTGTCCACCC TCGGCTTCGA CTACCCGCCG
 481 CGGGCCGACT TCTTCCGCAA GGAGTTGCGC GAGTTCCCTCC TGCTCGCCCG CGAACACAGCAG
 541 GTCGACCCGC TCAGCCTGAC CGGCTCCTAC GCCGGCGCCA TGGGCCTGCC ACAATTCTATG
 601 CCGAGCAGCT TCCCGCGCTA CGCGGTGGAC TTCGACGGCG ATGGCCACAT CAATATCTGG
 661 AGCGACCCGA CCGATGCCAT CGGTAGCGTC GCCAGCTACT TCAAGCAGCA CGGCTGGGTG
 721 ACCGGCGAGC CGGTGGTCTC GGTGGCCGAG ATCAACGACG AGAGCAGCGA GAGCGCGGTG
 781 ACCAGGGCGC TCGACCCGAC CATGAGCCTG GGCGAGCTGC GTGCCCCGGG CTGGCGCAC
 841 CACGATGCAC TGCGCGACGA CCAGAAGGTC ACGGCGATGC GTTCGTCTGG CGACAAGGGC
 901 ATCGAGTATT GGGTCGGTTT GCCGAACCTC TACGTGATCA CCCGCTATAA TCGCAGCGCC
 961 ATGTATGCCA TGGCGGTTTA TCAGCTGGCG GGCGAGATTG CCCGCGCGCG AGGTGCCAT
 1021 TGA

Figure 10 (SEQ ID NO: 22)

1 MKNAMQVLRT WAARGVQWVG VAGVIGLSGA AQAGDYDGSP QVAEFVSEMT RDYGFAGEQL
 61 MGLFRDVNRK QSILDAISRP AERVKQWKEY RPIFISDARI SRGVDFWNKH AEDLARAEKE
 121 YGVPAEIIIVS IIGVETFFGR NTGSYRVMDA LSTLGFDPYPP RADFRKELR EFLLLAREQQ
 181 VDPLSLTGSY AGAMGLPQFM PSSFRAYAVD FDGDGHINIW SDPTDAIGSV ASYFKQHGWV
 241 TGEPVVSVAE INDESAESAV TRGVDPMSL GELRARGWRT HDALRDDQKV TAMRFVGDKG
 301 IEYWVGLPNF YVITRYNRSA MYAMAVYQLA GEIARARGAH *

Figure 11 (SEQ ID NO: 23)

1 ATGCGCCGTA CCGCCCTCGC CCTGCCCTTG TTCCTTCTGG TCTCAGCATG CAGCAGCGAA
 61 CCGACGCCAC CACCGAAACC CGCCGCCAAA CCCCAGGCC GCACCGTCAT TTCACCCCGC
 121 CCCGTACGCC AGTCGGTGCA ACCGATACTG CCGCTCGCG GCGATTACGC GAACAATCCG
 181 GCGGCACAGC ACTTCATCGA CAGGATGGTC AGCCAGCACG GCTCAACCG CCAGCAACTG
 241 CACGATCTGT TCGCCCGAGAC CCAGCGCCTG GACTGGGTGA TCCGCCTGAT GGACCGGCAA
 301 GCCCGACCT ATACCCCACC CAGCGGACCG AACGGCGCCT GGCTCGCTA CGGAAAGAAG
 361 TTCGTCACGC CAGGCAACGT ACAGAACGGC GTGCTGTTCT GGGACCAATA CGAAACCGAC
 421 CTGCAACGGG CATCGCGCGT CTACGGCGTG CCGCCGGAGA TCATCGTCGG CATCATCGGC
 481 GTGGAAACCC GCTGGGGCG TGTGATGGC AAGACCGGA TCATCGATGC GCTGTCCACC
 541 CTGTCCTTCT CCTACCCCTCG CGCGCGGAA TTCTTCAGCG GCGAACTGGG GCAATTCTC
 601 CTCCAGGCGC GCAAGGAAGG CACCGACCCG CTGGCCCTGC GCGGTTCTA TGCCGGCGCC
 661 ATGGGCTACG GCCAGTTCAT GCCGTCTTCA TTCACCAAGT ACGGGTGGG CTTCGATGGC
 721 GATGGGCATA TCGACCTGTG GAATCCCGGT GACGCCATCG GCAGCGTCGC CAACTATTTC
 781 AAGCAGCACG GCTGGTCAG CGCGGATCGC GTGGCGGTTG CCGCCAGTGG CGGGCTCCC
 841 TCGCTGGAAG ATGGCTTCAA GACGCTGTAC CCGCTGGACG TGCTCGCTTC CGCCGGATTA
 901 CGCCCGCAGG GTCCGCTCGG CGGCCACCGG CAAGCCAGCC TGCTCGCCT GGACATGGGC
 961 AGGAACCTACC AGTACTGGTA CGGCCTGCCG AACTTCTACG TGATCACCCG CTATAACCAC
 1021 AGCACCCACT ACGCGATGGC CGTCTGGAA CTGGGCAAGG AAGTCGACCG GGTGCGTCAC
 1081 CGCTCCGTG TCAGGCAGGA TTAG

Figure 12 (SEQ ID NO: 24)

1 MRRTALALPL FLLVSACSSE PTTPPKPAAK PQARTVISPR PVRQSVQPII PLRGDYANNP
 61 AAQHFIDRMV SQHGFNRQQL HDLFAQTQRL DWVIRLMDRQ APTYTPPSGP NGAWLRYRKK
 121 FVTPGNVQNG VLFWDQYETD LQRASRVYGV PPEIIVGIIG VETRWGRVMG KTRIIDLST
 181 LSFSYPRRAE FFSGELEQFL LQARKEGTDP LALRGSYAGA MGYGQFMPSS FTKYAVDFDG

WO 03/042240

PCT/CA02/01740

241 DGHIDLWNPR DAIGSVANYF KQHGWVSGDR VAVPASGRAP SLEDGFKTLV PLDVLASAGL
 301 RPQGPLGGHR QASLLRLDMG RNYQYWYGLP NFYVITRYNH STHYAMAVWE LGKEVDRVRH
 361 RSVVRQD*

Figure 13

SPA-1	30	40	50	60	70	80
	ACAQKNPTVEYNQPAAPLQTAKAPFSGAGPAASVPAGAPNEAQP-GQSFEQWRDAFRQQAL					
SHB-PA104			MRSLLLSSLALLPALA--LAQPDASSFPSCLAGLQKKAQ			
			10	20	30	
SPA-1	90	100	110	120	130	140
	AGGIDAQTFDRAFAGVQPDPAVVEADRSQPEFTRPVWKYLEGALDPLRVRQGQARLAQHA					
SHB-PA104	40	50	60	70	80	90
	AQGISADSYERFTSGLQADLSVLDLLDAQPEFTTPLWDYLAGLVDEQRVSDGKAMLAQHD					
SPA-1	150	160	170	180	190	200
	RILGEVDARYAVDADAVVAIWGMESNYGSHMGNKNVIRSLATLAYEGRRPEFAHAQLLAA					
SHB-PA104	100	110	120	130	140	150
	KLLDQVAARYGVDKYTVVAVWGVESDYGRIFGKRPLLTSLSTLSCYGRQSFQGEFLAT					
SPA-1	210	220	230	240	250	260
	LKILQHGDVPASFMIGSWAGAMGQTQFIPTTHNQYAVDFDGDGKRDIWGSPGDALASTAN					
SHB-PA104	160	170	180	190	200	210
	LKLLQAGDIRDAGITGSWAGAFGHTQFMPSTYARIAVDFDGDGRDLVGSVPDALGSTAN					
SPA-1	270	280	290	300	310	320
	YLKASGWIAGQPWGFEVRLPAGFDYSLAELTIRKPLGEWQGMGVQGVNGGPLPSGLSSEQ					
SHB-PA104	220	230	240	250	260	270
	YLKKAGWRTGQPWGYPEVVKPADFPASLAGRGKRQPLSAWVARGVRRVDGQPLPGG--DEK					
SPA-1	330	340	350	360	370	380
	ASLLLPGHRGP AFLVLHNFRAILKYNNSAYALAVGLLADSFKGGRIVGAWPLEDVPL					
SHB-PA104	280	290	300	310	320	330
	AAILLPAGAQGP AFLVYRNYDAIYSYNAESYALAIALLSDRLRGSGGLVASWPTDDPGI					
SPA-1	390	400	410	420	430	440
	SRSQRIELQRQLAARGHDPGAVDGIIGANTRKAIRACQQEFGW-PADGYPTPALLDRLRT					
SHB-PA104	340	350	360	370	380	390
	SLERKQLQKALLARGYDGEADGLIGTSTRKAIQAEQKRLGLTPADGRAGRKILEALKG					
SPA-1	P					
SHB-PA104	AQP					

Figure 14

SPA-1	70	80	90	100	110	
	VPAGAPNEAQPGQSFQWRDAFRQQALAGGIDAQTFDRAFAGVQPDPAVVEADRSQP---					
SHB-PA105	20	30	40	50	60	70
	VQWVGVAGVIGLSGAAQAGDYDGSPQVAEFVSEMDYGFAGEQLMGLFRDVNRKQSILD					
SPA-1	120	130	140	150	160	170
	EFTRPV----WK-YLEGALDPLRVRQGQARLAQHARILGEVDARYAVDADAVVAIWGME					
SHB-PA105	80	90	100	110	120	130
	AISRPAERVKQWKEYRPIFISDARISRGVDFWNKHAEDLARAKEYGVPAEIIVSIIGVE					

WO 03/042240

PCT/CA02/01740

SPA-1	180	190	200	210	220	230
SHB-PA105	SNYSHMGNKNVIRSLATLAYER-GRRPEFAHAQLLAALKILQHGDVPASFMIGSWAGAMG : : : : : : : : : : : : : : : : : :					
SPA-1	140	150	160	170	180	190
SHB-PA105	240	250	260	270	280	290
SPA-1	QTQFIPTTHNQYAVDFDGDGKRDIGSPGDALASTANYLKASGWIAGQWPWGFEVRLPAGF : : : : : : : : : : : : : : : :					
SHB-PA105	200	210	220	230	240	250
SPA-1	300	310	320	330	340	
SHB-PA105	DYSLAELTIRKPLGEWQGMVQGVNGGPLPSGLSGEQ-ASLLLPAHGRPFLV-LHNFR : : : : : : : : : : : : : : :					
SPA-1	260	270	280	290	300	310
SHB-PA105	350	360	370	380	390	400
SPA-1	AILKYNNSAYALAVGLLADSKGGGRIVGAWPLEDVPLSRSQRIELQRQLAARGHDPGA : : : : : : : : : : : : : : : :					
SHB-PA105	320	330	340			

Figure 15

SPA-1	10	20	30	40	50	
SHB-PA106	MRNPERSALLKVSGLLGSTVAMGLGL-SSACAQKNPTVEYNQPAAPLQTAKFSGAGPA : : : : : : : : : : : : : : : :					
SPA-1	60	70	80	90	100	110
SHB-PA106	MRRTALALPLFLLVSACSSE-PTPP-PKPAAKPQARTVISPRPVR 50 60 70 80 90 100					
SPA-1	120	130	140	150	160	170
SHB-PA106	QPEFTRP-----VW-KYLEGALDPLRVRQGQARLAQHARILGEVDARYAVDADAVVAIWG : : : : : : : : : : : : : : : :					
SPA-1	180	190	200	210	220	
SHB-PA106	APTYTPSGPONGAWLRYRKKFVTPGNVQNGVLFWDQYETDLQRASRVYGVPEIIVGIIG 110 120 130 140 150 160					
SPA-1	230	240	250	260	270	280
SHB-PA106	MESNYSHMGNKNVIRSLATLAYER-GRRPEFAHAQLLA-ALKILQHGDVPASFMIGSWAG : : : : : : : : : : : : : : : :					
SPA-1	170	180	190	200	210	
SHB-PA106	VETRWGRVMGKTRIIDLSTLSFSYPRRAEFFSGELEQFLLQARKEGTDPLALR-GSYAG 170 180 190 200 210					
SPA-1	290	300	310	320	330	340
SHB-PA106	AMGQTQFIPTTHNQYAVDFDGDGKRDIGSPGDALASTANYLKASGWIAGQWPWGFEVRLP : : : : : : : : : : : : : : : :					
SPA-1	220	230	240	250	260	270
SHB-PA106	AMGYQFMPSSFTKYAVDFDGDGHIDLW-NPRDAIGSVANYFKQHGWVSGD---RVAVP					
SPA-1	350	360	370	380	390	400
SHB-PA106	HNFRAILKYNNSAYALAVGLLADSKGGGRIVGAWPLEDVPLSRSQRIELQRQLAARGH : : : : : :					
SHB-PA106	330	340	350	360		
SHB-PA106	PNFYVITRYNHSTHYAMAVWELGKEVDRVRHRSVRQD					

(SEQ ID NO: 2)

1 MRNPERSALL KVSGLLGSTV VAMGLGLSSA CAQKNPTVEY NQPAAPLQTK APPFGAGPAA
61 SVPAGAPNEA QPGQSFEQWR DAFRQQALAG GIDAQTFDRA FAGVQPDPAV VEADRSQPEF
121 TRPVWKYLEG ALDPLRVRQG QARLAQHARI LGEVDARYAV DADAVVAIWG MESNYGSHMG
181 NKNVIRSLAT LAYEGRRPEF AHAQLLAALK ILQHGDVPAS FMIGSWAGAM GQTQFIPTTH
241 NQYAVDFDGD GKRDIWGSPG DALASTANYL KASGWIAGQP WGFEVRLPAG FDYSLAELTI
301 RKPLGEWQGM GVQGVNNGGPL PSGLSGEQAS LLLPGHRGP AFLVLHNFRA ILKYNNSAY
361 ALAVGLLADS FKGGGRIVGA WPLEDVPLSR SQRIELQRQL AARGHDPGAV DGIIGANTRK
421 AIRACQQEFG WPADGYPTPA LLDRLRTP*